-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BDKZL9Z4D6xQ7edkb4CJ1Ldv618I9roTEdpZRplp5+0ZwG/7XvWhLVck7G5d+i/w waCXuj9C3UIEbiKdMDrv0Q== 0000950103-04-000425.txt : 20040324 0000950103-04-000425.hdr.sgml : 20040324 20040324133515 ACCESSION NUMBER: 0000950103-04-000425 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20040324 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 04686840 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 8-K 1 mar2404_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2004

               Shire Pharmaceuticals Group plc               
(Exact name of registrant as specified in its charter)

                           England and Wales                           
(State or other jurisdiction of incorporation)

0-29630
(Commission File Number)
98-0359573
(IRS Employer Identification No.)

 

Hampshire International Business Park, Chineham, Basingstoke,
                           Hampshire RG24 8EP England                           

(Address of principal executive offices)    (Zip code)

Registrant's telephone number, including area code         44 1256 894 000

______________________________________________________________________
(Former name or former address, if changed since last report)


Item 5. Other Events

     Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibit 99.1 and Exhibit 99.2 and which are incorporated by reference herein.

Item 7. Financial Statements and Exhibits

           (c) Exhibits. The following exhibits are filed herewith:
99.1         Press Release dated March 23, 2004
99.2         Press Release dated March 24, 2004


SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SHIRE PHARMACEUTICALS GROUP PLC
     
  By:

/s/ A C Russell                
Name: Angus Russell
Title:    Group Finance Director

Dated: March 24, 2004


EXHIBIT INDEX

Number    Description
99.1          Press Release dated March 23, 2004
99.2          Press Release dated March 24, 2004


 

EX-99.01 3 mar2404_ex9901.htm EX-99.01
Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com
 

7:00 am (ET) 12:00 noon (GMT)

 

Shire acquires FOSRENOL® patent rights

Basingstoke, UK – 23 March 2004 – Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that it has acquired the rights to the global patents for FOSRENOL, excluding Japan, from AnorMED Inc. for a consideration of up to $31 million.

Under the terms of the agreement, Shire will pay AnorMED US$18 million when FOSRENOL is approved in the United States and US$7 million when FOSRENOL is approved in the relevant EU countries. In consideration of these payments, Shire’s royalty obligations to AnorMED shall cease throughout the world, except for Japan, and title to the patents will be transferred to Shire upon payment.

The agreement also provides Shire a 12 month option, to purchase the Japanese patents for US$6M to be paid upon approval in Japan. On the exercise of the option, Shire’s royalty obligations to AnorMED for FOSRENOL sales in Japan also cease. If the option is not exercised AnorMED will continue to be entitled to FOSRENOL royalties in Japan.

For further information please contact:    
     
Investor Relations    
Cléa Rosenfeld + 44 1256 894 160
     
Media    
Jessica Mann + 44 1256 894 280
     
     
Notes to editors    
     
Shire Pharmaceuticals Group plc    

Shire Pharmaceuticals Group plc is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system, gastrointestinal and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com


THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialise, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialisation, the impact of competitive products, including, but not limited to, the impact on Shire’s Attention Deficit Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise, government regulation and approval, including but not limited to the expected product approval dates of lanthanum carbonate (FOSRENOL®), METHYPATCH®, XAGRID® and the adult indication for ADDERALL XR®, the implementation of the planned reorganisation and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission.


 

GRAPHIC 4 item1x5x1.jpg GRAPHIC begin 644 item1x5x1.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"M`3$#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@!#TZ$\C@'!ZCOD=.IYY''/2O+?%\7B MFRUL>)AKTUGX*\-Z%?:OJ&BZGW<>L2Z)K<<,6 MG:UI>L&^NK+4EBN9EAU"&54:!TS(D+2Q^=]&+XK\.C7U\*?VK`_B$VAO3IJ+ M<23+;KU>218F@A7S%?5O#VFWTEU:65[#&YVPV$5K$)&3S%>38P\HT+QB?!NH:I8> M&-&L]6$%SJ?]K^+_`!=?7UAJ7BC6M)Q)KFG:;J#+<6UO-`3NT[2KRY3[3%E8 MT)#,>VI1I8ARJ86FJ247)TW)*R323UTMV5W*3=_A3D!]A2AB`5W$J<[5;&X= MQ@L@/MET`/))'!\?\46OB#PM+JOC1=>\2:MH6E:>+W_A#HKJV7==)>;16%$EAU'1I)X8K]%N[A9`RDI\V3],65_97\0ELKNWO(U)1 MI+>9)T5UX96>,LH;O@D$C#`$$&O%?B3\/;.+08_^$2T*.SMFUBQO/%6G>&X; M;3M5U[0K>0M=6-O.B*TDJEA/%:EA%*Z8:-L`#!^%/A75;#Q)#K-I:C1_"EOH MUUIEM;3V$FB:SK,[W`>TG\0Z,JBT_M73;>%X'U6#Y-1B>.;S6EDFC7TZ_P!5 MQ5+V\8T\/.G3LJ<8Q4)Y$;F%)I(\NL32!5?Q#/H5C/XJL[*PUUXR;^TT^=KJVA<,0H63+@L4"LZQR31AC\LAR0 M-\,K=#G'7@\>QXX//0\UBZ_I=QK&D:AI5IJU[H=Q>6[1PZKI_E_;K*0D%9H/ M.1HVVX^8$9QD9!-5+S5+'P?H!O=74 M^`D442[RVU5)!-4DY-1BG*3T44KMMNR27FVEZL#I2R@X.<\#H3]XX'(&.I&? M3J<"G5\H0_%#QSXDO-9\:^'8M*@\*>$HW^U>&;^]@MM2U?3U,5S=ZG.LG[VW MNH8(`=/0XC=4ZBT<9N.MDFM&N:Z:`VZ***YP"B MBB@`HHHH`****`"OF7XF_`GQSX_^+OPP^(NE?M#_`!A^'_@WP/%JJ>+/@WX- MU#P]IW@WXH3S2Q3:'<>(=2;1)/%6FKI4XG>^ATC7HEUK3VAT]DT]X);B\^FJ M0@'MZ?I_G]3ZTX3J4I\]-QNH2C:48S34TXRTFI)24?@FDI1D[III-)JZ:NTF MFG9V=GHQ:***0PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`$8$C M@X.0?R[?C7D7B;X>:-&GB#7K2RU._DN;.\NKSPG#>LV@Z_?B$;'NM+>WD#7< MH"HUQ:20W91%C1VSMKUZD*@]1GIP2<<9[=._7OQGH,53E*G;E;MHGJ[M+6UU M9^6Z=KZ@?%*>+?$T-WI,NDBXD\;WUE80V/AGPO?7$F@Z9:V\L$:34;-,L^Q]E#('/)KPO]HZ?X\V'P3^ M)%_^S-I7P_USXZ6WAV^G^'.D_$Z\U2Q\%WNO1AFABU2?2(#=/<&`R?V;;7%S MI^EW>J+9VVJZSHFFRW>KVG<>%O'UAXGNIM-^QWVCZI!IMEJYL=02VD\[2M1" M"SU&ROK&YO-/O+:5G"[H;ARK$*PS7=%1(@#@$':Q'.-RD,".AX8`CZ5P1@\- M6IQJT(U/92A45.O[\)\K349*,HR<)7U49)-75^R:OU:]'8Y;PE>>(3X9\/OX MTM=+LO%TVBZ1)XGL_#\UW?:%9>(FTJU;7+71[V\L["\N=)BU9+^+3;N\LK2> MZM4MY9H()KB.`]2LBL0!GD$]NWKS]?R-?,G[3/[/FM_'_1/`FC>'_CE\8/@3 M-X)^)G@OXBW6J?"'6K/2KKQA9^%-474+KP-XICU#2]1@OO#&O1QJM[:!EB^V M165Y?6FI6UJ^F:AZ3XB^,GPL\&>._`7PT\6?$7PEX>^(7Q3N-9A^'/@C6=;T MZP\2>-)/#EB-0UY/#.DS3)?ZFFE61^TWAAAE$3,D1GW.L9KV;G*FJ%ZM2H\1 M4JX>E0K2>'A32FG=)ITW%SGS7<:=.#4FM&-+\%_P#U6L?6]!TGQ%:166LV%O MJ-K#>6M_';W*[HQ=6UM=*U6QU$Z/X@LA`UYH6JB MSGF.GZS:+ M>BN%TFDW9O9=7Z+J>2_%W0?`$-O::[XA\,W>MZR\]MI6DZ?HYNX[K6;DJ9+; M3[E+,)'-:0K&7;[0"(H$,<&658JJ^$/&7BKP]-::5\1M.T+PWIU]#>W>CSPZ MEH6F66B6L`B%EH,MC-.MU<7*`M&EQ"&C+`^>8R4!]Z>.&91)M67^.-P!)M;8 MRJZ9RN0K,%(_O-C[QS\X>+?`VN7?CG5M>GTFXUI[_P#LH^%[]X;;4](TBW@M MY[;5M"U_1+R^MW&FZJ98UGN[%)[B)GCNK4V\L$A?LHUH5H+#5Y7]FI M$9-)=1U+0I;74-&T719-2Q*EK(TD$U M_9Z,TX@NTL(YY--CB"^6T*-L^C;"\AO[.WO()DG@NH(KJ">,DQS6\ZB6">,E M$)BEB9'0E0<'!)()KFJT:E&;C-7BW>E42:52GLII=+M2T\K[-`7:*.O2BLP" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@!"H.,]O\XKAO&O@O_A*DTR[M-0_LG7M!NY+W1=3-LE]!!)/"UO6EU"Q6>-I$D&`898F&ZNZHI0O2J.K3TJ-K7O:R5[WTLMMFKJVH'F M/@;X;Z;X*N;G5O,2;6]6L[2ROWMA);Z7!Y!#O%I&GS2W!L+*65%D%H)Y$A** M(\!FKTX=!CTKF_%>CWVO:-<:7INMWOAZ[N&B\O5;!87N8/+E21E59E8%954H MQ7#`'.<<5>-];:=%96M]J$"32&.RBEO)HH)KVZ6/Y1&C;%EGF5&D98P`7)$8 M^ZM7.O)?%GP/^$GC3Q[\/?BIXO\`AYX0 M\1?$;X47&K3_``W\;:KH6GWOB;P7-K^GR:5JQT+5YX'NK2.^M)Y4E@C9+?S& M%V(/MJBX'K*'<,GGG_`TXC/^1_6HC*O3E.=&M.E-PG3C.FY0DJ=6+IU:J^*M8^)%AHU[KMA\-?`7]C:O=:EJWA73?!T'B'Q2WC*:TTQ]/M-9U70] M.TGPQ?:OH%]')JLU_'':?E#_`,$^/B[\'?@-\W_``QE\6?C%K_CS]JK MQ;/\-?VX_@1\5]?\-^*9]+Q1K%G-::P-1_M7E\-:`=9F\3'1M-/B-]+&C-KJV%FFMOHT= MTU^FC?VPD`U(:6+]C>+8_:3;+=LTZQ"1F)_"#]M#X.?M"_'OX[^-/V>_V,OV M=O!/[).HZAX;L-=^._\`P4GUCX>^"/#'BG4=!\307LMOX/\`@IXI\&L/'GB3 M7]:NM-N+/QCJMQK&F:CH5C#=Z=J']DVNKZ1X@U3]*X;SS*I9;5X?>3X;`T*V M"J2S;,L1C:4J.,JNC7P\\3F-)X7ZS7PV#G5PV,P."P7M<4L71A&A%3J<\?*Q M="5.2K?6*LI^T@Z=.,92Y$FG)1;FDDVES.5EHWJKG[[VI4P1%""C*64@`!@Q M+;@%)7#9R,$@@YR:E90<'&2N<=NO4$X/!P">.H'I7X1_L0_\%8OAG<7EO^S= M^TE^T1\+_B+\6O#_`,2;GX.>'OC?\(/A[\9]/^`_C?4+&VM[/PMH_B+XL^.M M&N/![?&#Q4UM?W5[8Z9XDNO#^LZCO3P]K6LR/YLW[KQ.Q#-(Z;0<`\#!`);/ MZ$9`.,DU\)F648_)L1]2Q^&Q%)I2=#$5<+B,+0QM&E*$8XK"QQ5*C5G0K%+O5M7.AKIL$FL36WB!A:ZEH7V]Y;>"YTJY>Z:1X[T/*S!6,AE M5'6#1O&WC#1O&,NB/%!<>';;7?#VAZ=X&=:B6TT'58[P$W3&W>W M\O4EFC:P+R*+:ZE8[1]):EI]GJ=E=6-_;Q7=I=P/;W-M.B2130RC;(CHY52" MI/.X%2`R$,!7#>&/A_H7A'4+_5[6]U2YFETZ+3EDU;47O(M/TRVN6O4MK9G5 M3%!%+M9=[RLJQ*!*%%3'$0G1JPKIRG&GRX>R32?->[VY=Y7:3;[ZFAZ'YF!T M`XXW-M'L.AP>W3K3T<."0",'!!ZYP#_6OEOQC\5;SQ+JT'A3P7JJZ#IWN0JQ70R%:WO"(S%=VQ4B*56:-W7&)G@L12HPJU8J M$I).5*3?M8)V5YI)P5VU[L9RDN97BDP/6:*3(SC(SUQGG'KBEKE`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"N>UGPMH>OR:?-J^FVE_-I5]%J6G27,;N;2\A8F.9-LL8+("=H;*J<'!*BN MAHH`Y2X\4V.G^(=*\*O9ZG)=ZG97-W#=P64LNFP1VK;/+N;M6]C;S7=U+%;VUO%)-<7$T@C@@BB1I'DEE8;4C55)9FP!P!EB%, MXC0,6`.2,?>8C&<\`D@$]R`"P`!)``'@OQ"\'_$3QUJ%]HJW^GZ#X.M;-)[* M2V:6:ZUJ_P`[XK34HXI%>&VCN(X_,2%>C!T>5E7&L(1J2C'F5)*#=2=; M2$;98B&RI.VLOXI>`[7XG?#CQ]\-]1U&_P!(L/B%X,\4^![W5M'N9+/6-,M/ M%>AW^A76H:5"00=.I2J2?PSA47(W"<6G[LXW MC>]G9/9I-+83BI73U3BXM/5-/>Z>E^E_N9_(O\1O^"5^G_LZ?#GX5>%OV@OB M=\)/V=?@3X=^(/P'^'?C#XJ?`V;XA7^I?M?:EHGQ&TRY^%=M\9/@/J/A27PM M\/?B@EW:6]Q/\OZY\2?@'\3O!7@[5/B#X7T7XV: M'J_AJR\.7^E_$OPII.L7_A'QAX'\1R:0\MAW[27Q5@N;[]G+XB_#GX;7$'[,<5_KWA_POX9T3P[I7C:_?6/A M[K7Q0\4;M;TZQNK::R\5:1J;27.J_HV79QA>+Z>)P.=QIXO.Z[QTLO=:C4P] M.G7KNE6Q688?$X24'/$QH4,17K4,53Q*K3P.!RW`TXT<55IP\FI2J8.:GA[J MA%WJ);)75H..TN9R4.;=NTC"`DD!54\_*2@"% MC\O%/FC\U&C(1D965E==RMNX*NI^5XV4NKJ1SD8]1_/=_P`$+?&7[17CSX?6 MGC.[\=>*/''[*FL?#A=)B'Q>^(EY\4/BCX4_:H\%^*O^$=^*=OX2\;ZKIT>K M^(/@?XWTWRO&7A,:KKFO2Z!=W2:%9RZ:D%YI=K^]&H>/?!&C>)-#\&ZUXS\* M:3XO\46>K:CX9\*:GXBT>P\2>(M/T`6S:[?:%H5U>0ZIJ]GHJWMF=6NM/M;B M#31=VQO'A$\6_P"#S;*JV49EBLNJ5J>)J8>512G04K)4TW54X22E3E1Y9NI& M7-R17,YM>\>C1KQK4HU?@4^6T9->ZY**4;[2;D]+=7R[JQQ'CGP'=ZAX4_X0 MWP?I^AZ-IFK:@1JLH@5%L;>1OM,^H65DBB*:[EFCVM(Y\[YL(X`X\DL/&>G> M!&UJT\*^$/#FFZ/83:G83ZSJYFLY_&6M^'55[RRBNX+=X+#49?->6UM]0-Q' M<9Q#M9F-?7>8CG:R$_,`59<@D$$*0<@\'.W!X)ZYKQ[Q3\-M+9/$>M:;I%WK M%_J5K=7=UX3?4Q;>'_$NHF/:CWUK+;4EMOKT[]/ZU.KA^('AU-(\.:SJM_ M::2OBI-/72;>ZE*W%Q<:BD;P6JH%)9\R*K.H*?Q!MHKN48.H=2"&&00201[$ M@?RKXTO-2NO"OBO1[WQ-I&GZ_P".7M-/$5M-R"STBR2;[)>1Q M7;R)L.H3A+82XPPF6(GZ8\$^*F\5:0U[+:'3[VSOKW2M6LOM,-Y%:ZC92QB1 M;:\B58[RS=)DDAN(U5=I\LJKHX5XG"RI+F@UR.TE+FC)B3LN9637M+1C- MZQ25DP[6BD!!Z$'@'@YX/0_0]O6EKENN^^J\UW`****`"BBB@`HHJ*>>"U@F MN;F:*WMK>*2>XN)Y$A@@@A0R2S32R%8XHHHU9Y)'941%+,0H)H`EHKX`_P"' ML7_!++_I)9^P!_XF1^SK_P#/&KU/PK^W?^P]X[^*S?`CP1^V5^RGXR^."ZQX ME\/-\&O"O[0_PB\0_%9=?\&6NK7OC#0V^'>D>,+SQ>-8\*66@ZY=^)=,.CB] MT*UT75KC5(+6+3KQX0#ZLHKX/C_X*F_\$QIM+O->-/!'PW\?_M=?LP>!OB)\3-*\*:[\./`7C'X^_"GPSXT M^(&B>.[Z73/`^L^"/"VM>+++7/%>E>,M2AFT_P`*:CH-C?VGB&^BEM-(FO+B M-XP`?3U%?`'_``]B_P""67_22S]@#_Q,C]G7_P">-7LO@C]M7]C;XF?#WQY\ M7/AO^UK^S+\0?A1\++>XNOB=\3O!'QY^%GBOX>_#BUM+)-2N[GQYXTT'Q5?^ M&_"%O:Z=)'?W$WB#4M.CALI$NI&6!ED(!]-45\+S?\%0_P#@F?;:%IOBFX_X M*(_L+0>&=9U?6]`TCQ'-^UO\`8M"U77?#5GH&H^(]$TW5W^("Z??:OH&G^*_ M"U]K>FVMQ+>:59^)=`NKZ&"#6=.>Y]:^!_[8O[(O[3>IZ[HO[-O[4_[./[0> ML^%K"UU3Q-I/P/\`CA\,OBQJ?AW3+ZX>TLM1UVP\!^)]?NM(L+RZCDMK6[U" M*WM[BX1X89'D5E`!]'45X^_[0OP!C^,B?LZR?''X/Q_M!2Z`/%D?P*?XF>"T M^,DGA9HFF7Q*GPQ;6QXV?0#"K2C65T,Z<8E:07.P$U+IGQ^^!&M?%?6O@-H_ MQK^$FK?'+PWI,6O^(O@QIGQ(\'7_`,5]!T*<*T&M:U\.K769?%^EZ3,KH8M2 MOM'@LY`ZE)F##(!ZW17)^-?'O@;X:^'[KQ9\1?&GA/P#X6L2!?>)?&OB/1_" MOA^S)220"ZUG7;RPTZW)CBED`FN4)2*1A\J,1UE`!1110`4444`%%%%`!111 M0`4QS@9S@Y&,YP3Z8!&1GD=#SWI-75KM>:W^0'AGC'P M-97-WKWC3QY?R^)-!T.QN]0T7PVT3VEAI-M;64MQT1'#QJ8BC?5-S:V]W;SVMS;PW%O,"W21.VAB(U$\/B/>YDE0IQTC% MQ32<5MS2;CS-+F;UNVK,/;U(6-5"G+,5(P$P68[W`8("-Q+<#&O&.BZAX8\8:%H_BGPWK5L]EJ_A[Q#I5AK>AZM9LR.]IJ>DZG;W=C?6SNB M,8+F"2(LH)4D*1\R_#/77T.75-5N_%4UWH7AB^US3O%>JW^M7FJZ5K<5U,MW MX5UK2PXF"ZFV);"_M;)HS(\T2>3.^TGZ<\.^)M"\56$.IZ'J-OJ-M*6&Z(2) M+!(IRT5S;SI'E[>>Y\4?ME?%;QG^QU^S1-J_[,'[,>L_ M&7Q<-1T;X=?#?X2_"W0K/3O#_AS4O%+W.F:%XAUW2-%MXWT[P)HVL362ZU%I M%I"D\MU#;75WH-C>WOB#2_Y@OC;\.OB+\$?B+XE\<_\`!4ZY^/'CC]N#XU_# M6#Q_^PI\/?@MX$-C.L/C+5/!NM:EJU]8M#J(+_`$]/N>". M(L/EF,^H5\%1=3-/:4:^92JSI8S&5ZU;!0R_+GCJGM*>6X#ZS&4\QJ0IR>-P M4Z^'KQFE32\S'853A>%TJ4'[.DES4(7^*K4HW2J5(J[IV<>5Q35K-OZW_P"" M;7CG]J#XA_L<_!KQ?^V/X8G\*_'S5M'U@^*]/O\`1XO#^JW>GV>OZM8^#]*"VT37]=\)P:7JNLZ9;VEE#;7=](?LED7%N?O-/F^8]1E>_OW(&>N*_C MX_8E^+?[57A;]J;]FB#PC^U=\5_VOO!'CGQ)XM\5_'7XSW_QDU#Q[^RO)\`) MOAP?%6M+\2_#_B+5+^;]EK]HGX.Z]+:VNF^"?/T2U\9Z'<:1>6YN8I-7TG3O MWF_90_X*">$?VS/C+\;?!_P.\%>+-=^!WP;L].T@_M+/_$]]8U*P MU[P=X`AG=K[Q+INEZ7;VVHVWBFS$EE=K)YTVGPV^H>&=3\0>?Q1PQBL+C\RQ M]'ZK7R^/MLQKO`+V.#P,:^/E1IT73Q$HU,/>JI0R_#UO8XBMAE[18>FHN,=< M)C8U*-.,J=2,E:'P\WM%I^\IVTG36CG):)V;[GW%XB^'VFZUJ#:LNHZKIU_= MV<>DZB;+^SYK35M+21Y4L]4T_4;&\LIXX@T@BGCAAN85/R2_>#?/DGBA?"=C MJ&F:<6\`:!H&OZIIZV^DZEI]WXA%TZ(L%_X@T+6+>674-.O9`L]L^F7,+060 MAMXP%CCD7[#7!`W$,?O#N![CK^!Z_K7(^(/!>@ZW10\#>*'U?1-!_MU[33_$]_I-K>7>E/-!%?MO5W%P+#SG MN88[B,BZ6(J5A2".<@,?'%YID*0:)X@\,XDT[Q+X;UA&5&758X8+6;3[*>W>=+J.%[4B.X MV>^>%?BYX4\17.F:=;-K<)U,2Q:/J6J:3-9:;KCVF]9S8W09XS*3#*QMYS%* MI!C\L.-E5B,.HR]M1_>1J>]/D4O9T;I-PBVWHFFDM&U%2M9H#UFBD!!)`[8S MP>_3GH?PI:Y@"BBB@`HHJ*>%+B":WD,JQSQ20NT$\]K.J2H48PW-M)#6*>%\212)(JL`#\$OV4_$'[9=GX\_X*">&O@M^SE^S+\3_@QK?_``4_ M^*NF>./$OQ(_:.\;>%/B);>'?$_:+.[TZ%H8+'6\'_`(*C^#-0^%GQ2^!7_!0G_@GMI.E^(OVW M=`^$WCW0O$7ACX8>#O"/CU/VC/V"SX6L]<\#+/Q#9?!WQ!;_## MXA?!"_L_%5O/XQ\=VOA7X.:9E/^V- MIFB?$S6/$/B'XCZ/I_\`P4U_X*766E_$#7_%UG#IWBS7/&^GVW[7,=IXKUCQ M/I]O;V'B'4]>AO[W6K."&UU*>Y@B1%]Z^#G["G[-OP#^)7Q2^+GPMT'XF:)X M[^,GAVS\(>.K_6/VC/VC_'&C/X6TB]OK[PWX>\(>#O'GQ9\3>#/AGH_@LZGJ M%CX`L/AIX?\`"-M\/M#O+CP[X)CT#0)6TT@'Y,?MF:3\#X/^"2_P#\<_L96? M@SXF>%/BO^V?_P`$X_CEX/\`%?B354\,1?';XF?%']O?X`^+-:^('QA\;Z%X M,\3ZMI_B_P")?C#5[V;XI>*QX$\2:_H%[J&LP)X/OGTF'PQ7T'XCUK]J[Q-_ MP43_`.">$_[3'P#_`&9OA=8Z18?M?R>#-:^"O[4'Q(_:'UVZU2\^#VB6^JV> MI:?X_P#V-OV9H?"M@=/6-EU+2M>\2W&H2YLKG2K2!%NF[/3_`/@AO_P3BTGP ME=^`-*\`_M'Z9X$O_B+;_%^^\%:?_P`%"?\`@HA9^$KSXM6?B:R\:VGQ1N_# M=M^U3'HUQ\1;7QEIVG^+;?QM-9/XE@\36%EKT6IKJMK!=Q_4WQ'_`&"?V%O!GQQ\ M/^$/$^J^,+$1Z1\2M=\7:#KVN?%308+;P_\`$C4?%6B6MOI\0!^!'[0FG76A M_P#!/_\`;1?P%X8\+77B.#_@X/\``FM>&]!U2_D\&^&]7\97W_!2/]G&\@77 M?$.C>&?%=_X>M=?UFZ=/$'B>P\)>)]5LX+^_U1-"UZZ!T^\^G_!OBGXI^'_^ M"Z/P;U7]L+X/_"S]G?XE_'S]BCXR_"_]GJ+]F3XD:I\?/!'[0B?#;Q-X'^)7 MQ5M_VA/BCXM^$'[.WCJPUOX0Z!!HT_P5T&^^#EYX9%KXK^)$,-.T+XU:W\1O&?P_U;X67GQA^(7[77[7GQ5^.GAKX?Z]-: MW.M>&/AA\=?B=\=/%_Q@^#=CJEW8V-Y?2?"3QMX)N[B]LK*]DN6NK2WFC`/B M7_@GCX!\%Z3_`,$;_`GB;2O#.D:;K>E_LD?'_P`#Z7>V-I':C2O"*^*?BCJI M\/:7:P!+/3=,EU"WM;FXM[*W@%R]CIXN#*FGV2P?4G_!*/PAX9G_`."<'_!, M3Q[+HMBWC+2_^";G[)WA"Q\1",KJ4/AG7?@1\'=9U316E1E6>QN=5\.:/?)' M<)*;6>U=K1H!>7HN>P^'_P#P34_9'^%G[+?B']B[X?>'?C/X6_9L\2H+6Z^' MNG?M"/$EOJ M?B"VU_P_J5OXF\0Q:G]$?L\?L]_"S]E?X/\`@KX"_!/3/%&A?"OX,/'/B^#POX?L8H-)\+^&O[?;0O M"VAVEEH7AW3]+T>RM+&$`_G3_:,^'O[2'P;\&W'[,/B/X1:]XD^-_P`>O^"S M'PS^/_[*G[6>B?$/X470\4Z'XK_:\T?X_>(H#X:NOB#;?'[2O%GP#_9+\*^/ M_ACXYTNW^'LOPYTKX&>&O+TOQO\`\(K;S>%;-=7\'?M._"R;]B#]CKQO^SM? MVW[1^A_\%>+[XV_#/]K;PUXI^$GBCPE\1_@!K'QD^+7QY_:&^,ATG3/&6N?' MSPEJE]^S%XF\1?L\_&6+XA?##P7X2F\=>/\`PAH7AKQI?Z+XCT(:-_07X"_9 M1^!/PY^+7C'X\:%X2U?6/C+XWG\4?VA\2OB/\0_B5\8/%WA[1/&6L6&O^(_` M?PSU?XL^,/&MQ\'?A1J&L:3I%^GP?^$S>"OA983:/HXTWP?9QZ3IZ6U_X7_L MR?!;X/\`C;QM\2_!OA?5;CXE?$1[B/Q9\1_'GCSXA_%KX@WND3ZQ=Z]%X0T_ MQM\5O%?C3Q/X>^'FEZK>37'A_P"&WAS5=)\`>&D2UM/#WAO3+.QLK>W`/A;_ M`(+;_#CX>>/?^"--2^'$G@;QY\/-0\6>%]#\1WW@/QS:>/? M#6B6OC/P9=ZQ8WEQX7\5VVBZYK>D6_B+0Y+'6(=+UC5-/CO%M-0NXIOUDKY$ M^-O[#7[/'[1GP3U/]GCXS6?QD\:?"36_'6I_$/7?#\G[4G[4FAZMKVMZKJNM MZW+HVN^.?#/QET;Q]K7PYL-4UZXN_#_PBU3Q/=_"CPLVF>%(O#7@O28/!'@V M+0?IGPAX7TSP1X4\->#-&NO$5[I'A30=)\.:7>>+_&'BWX@^*[K3]%L8-.L[ MCQ+X\\>ZWXE\<>,]>FM[>.35O%/C#Q%KOB?7KYI]4US5]1U.ZN;N8`Z*BBB@ M`HHHH`****`"BBB@`HHHH`*:Z*X`89`(."`1D>H((/Y4ZB@#Q3XF^#;_`%39 M=:7IJZYIQT?4='U/PHMY'I<<[7LMK>66M6,C0/9IJNF7ME#+&\J&3RW80M&[ M!UTOAAX2OO#>E)JGB"9CXLU33M+MO$;O<&6W+:)#=06,ISE?M?V*=8[RZ#A) M_(B.Q1&!7K-<#\1/"FH^,]$70[+7)=$MKJXB35F@@CEEO=+,D9NK-)6(:+S$ M4@I_J;G/DW(,#,*Z%B)SI0PTY0ITW-*=7EG*HZ?,N6-E+5II6:5VXQYFTK`< MY)\:?"D?B-]%21Y=)MU6"]\71[W\/6>JS$_9-+GO$B:))+E5<+=-*ENLQCB! M<2"0>KQ&.Y59T=9(Y%5XGC='1T)W!T90RE2`-CI(P8'>I5@I'R)JFD'1]5\5 M?#OP1K5O8^%9/#LMQXR_X2:`W6B>&[DQ1P3W=O=SJ<7VIV[Q.P;?;Q21J8]K MJ/+]L^&7B;P8NC:;X2T3Q1!K=WHVG*I9TN+>:[@CE9)+JV2Z2(7-LLSE$DM@ MT8C\O&4PQTQ6%I0I4Y4%6FURS;J>\O922Y9U.6*5.=^:T)7=N62;O<32>Y\3 M_MM_\$^M(_;`A^'G@_5?B7XN^'GP%TGQ3J/B_P".GP<^&MAH'AD?M"/;V"/X M"/%'Q7^'?C#7OA'IW@>XU_PE^S_`/L.?L_?#CPAXU\)?`74_`'Q1_X0B+X` M_MA_`VT\*1?%;0-3^)>C:AH5]X*^+6F7:6,VN/?6MQ);ZKXCT"Q/]NTF9$,2 MX);(?,B@[<$,,;7W`GY2AV\,'-+^(FG,]YIZZGHMK\13H]SK6C2:SX<@U/0;#5R\\ MFDS7MM=_-';%!]1PYQ#0HT8Y/G&'HX["U\1A50JXRG1E2PM2=>+Q%5^WI5XT M?K,>18G,%1KXNCAJ+IT?#]1\8>`K+XUV_A#P_X@\>_""R\7:/?>-_`U]JVC6.I MWMCKGA:*]E\0Z5%83WBP-+J=A;_)Y;LP$@(]V5V.,@^`><8R.>X'/) M`R?XSM`^!_[4GCC]I[P)HVAZ;\3?!?BC]G_QC\/?&W[0'[:W[5FA^`X?VH_! M?BKP[X&U/5O&W[.7PA^*_P`)-=N[[]J3X>?$KX?*^H:/X(O&?PGM/BIX(N/" MB?%_P1X/UZ]\-^)O%GPXU:WU/6=%\066@ZQ8WMEK&D/J-KXKTA(OM6KZ#:6O MF.O/GO"E;+J=/%X#$3S'"TL-"OF$J%+FIY?.LJM2BJ\HRDU1Q%"E5Q&&514Z ML<-3=2I",(J4IP>.C4;P]1>RJ7Y:7M':55QLI*-[1E*,M)^SO#>S?3[R\7^% M[+Q9X?U'P_>/+#%J-OY:W,6T2V\L4J7%O(OR$N$GC1RC!D<+M<'(KS+P[\)K MF#7]/\1>*-2L[S4--O3-;1^'X9](TF\FAL6M+;5-3TJ>6:W.MB*1K>XO-/6U M^U0I&ERDH7CW8.I&1G\B.Q/?'H1]:CN83<6\\`DEA,T4D7G02&*>+S%*>;#( M.8Y8\[XW_A<`U\M3K3IP<*=1J$FY.,6FFY:-]=^7[UW1ZFSL]_Z_S)0,=R>F M`<<8^@'ZYI:Y#38-/\!>&(HM6UNXET_2+8FYUK7+OS)2OF,3)ZM[N&&XMI4GM[B-98)HCOBEB8!ED1URI5@009_$KP2_C#PUJFEZ8]I:7]Y-ILTSS1ND.I1Z9<+ MK:HEK;SQZ3>QQ?:;3P_O82W%K=QG[-+Y7D*,L!]-IR3TT,=5I..'G:>';[!6DHN44Y*-N:5P\P\"Z_J(U35(_%_BS1#XAU2X@DMO!] MI?V,G_"/V<*82V8!EGDU"1)XOM:(,!TW[26.WV-@K$Y8XX&!C^$Y'(7=D,3P M&XYXZU\477@#5]$L+JPU:2V\.64%Q:7FL^+=9DM[_2[R^L]2CD_MS0+UKJ/6 M;#6+NU1;2XTV2.>SEC(<2B8$M[]H_P`5-(U#5;7339RQZ5J5\=+\.^*(+RPO MM#UZ]$7GFWBEM+F6XLIV4R;(+^&&9C&XV8V,^^+P\6^?#2]JN><&N7E25-1V MLVG=-VCJTES2>US5:K^K?\&VY\]?MU_LCS?M:_"KPOH/AOQE'\/OBC\*?BWX M$^._P>\87^C1>(O#FF_$[X=2:@_AY?&7AE[BQ'B+PGJEIJ5_HNN:='>6UZ+* M\:XTZXCO(QY_\^/CC1OVG/\`@GK\0/#OA'PK\$?@1^T-^WE\6/''[3?[3'P+ ML/AQX6\7:=\'OV9?A1J_A_2E^.6A?"O2-<\0^%_%OQ$USQ[>PW6LV?PKMM1M M;'2]4NKFZT6&_P!2UF)+O^N]6W'&,<9Z_P#UJ^5_VGOV-O@9^USIOA:W^,'A MW4YM=^'FJW7B#X9>/_!_B?7O`7Q)^&WB"^LGTW4-7\%>._"EYIWB#1)M2TU_ ML.HV\=W+I]]`J+>6-QL3'K\/\2K+(_V9F=.&-R*HL1*IA72O4]O5BK1E7ISH MXF>$G5C2J8C"+$TX5O9^S4HTJN*H8GDKX2%2?MJ35'$*/+&KR\Z2M;X+I7=M M^CUZ'QW_`,$L_P#@H#XM_;8TSXY>$OB!9^!]2\:_L_ZW\.]/U3XD_"VR\3Z- M\/\`Q]IOQ,\*7?BO2(X_"OC6,>*_`OC[PB+"\\/_`!*\#:S/=S^'-?B2W6X_ M>O;P?K8IRH/7/^-?$L^H_L?_`/!.GP#ITOB?Q)X(^#&@?$OX@Z-I&H>,/%=_ M)_PD/Q3^*NLZ9#IP\1^.?%-TMUK7C'QMK&G:(EYXG\;>);J>X%O97FN^)=8M MK*WOM2C^V8R"BD$$'/(SZG/7!X.1R!]*\C-OJ57,*^-RO`XC`Y5BY-82-:$X MPJ2P\*,,1.G.;<)=2I6TUGJ%M!>6EQ&T4]K1S7.>(-;'A M>TT^2UT+5=6BEOK'3([;0[-)S917UU?57Z76E^AL%%%%(!N]?7]#_A1O7U_0_X5#10!-O7U_0_X4C2 MHHRS8&<=">?P%15\[_M-_M4?!']CSX1>)/CG^T'XVT_P#\._"\G.4I2>D8Q2;;>B6K/H@W4"G!DP^*OC#2/`45[*RIY, MUKX/\':=X_U34GN6?;:V+:YIFH2#*2VT4XE@A^<-4_X.FOVT_A_(MQ\3_P!C M/X$:&FIBZ73/"5UXU\;>%_'UKY0C$=WKOAV_N-;US3;1VFCDMI=:\/\`AZWU M>W+RZ/-JPC):22K4J%6%36]N5*UM;]/[GTN M(9"51\D$@C:XY4X/50.#3O-C+;=WS>F&_O*O7&.KJ/Q]`UUXHU^#2/!FHP_L?R_%?P1=F^FAMM.L==^(GC M?XT70\/:E/,XMI;W6]"TSPQ'M34+C5+&UDN+2P_H7@^%?_!9OX33V7C+PY^V M)^S+^V?H]KY-]K'PJ^*'[/-O^SIJ?B32;VT9[A_/SS@?,N'*E+"YUCLJR[,:L:"Q$\S2J3J* M#5&EF#RJ.55*K0<'@]<`^GH12>8F<9Y^A^OI7PY\2 M?V[/AC\'?V(+G]NKX@>%/B!:_#G1/AUX3\?^(_!6AZ;H>I?$?1%\2:GH.@W7 MAM],O]:T'0[C6_#6O:\FF:XG]O6UJAL-0EL)KL)##/\`C=!_P=;?\$X[JYBM MHOAG^U\LEQ<06T4DWPT^&"V^^YG2!&:1/C7)(44N7D$4,LB1HS!&;:K^5EO" M7%>O&9YE67SHPQF-P^&GB(QG1A6JNG.49-P4N7VC/5332::::336J:>J:?8FWKZ]?8_X4;UYYZ8SP M>YP.WOP+F_:!^-FB>/==\$0>+O#'@M[' MX<:5H6M^)&U3Q3]N.GSKI_B#Q)X5T\V,7]FW'VN5]626/,?E6\^\[=,-AL7C ML7AL!@<:=& MA2=:K4D[1A332&[W7OA_\`#2TT&TU[QOXAT[PSH\VLW>F_ M&/5KVUT]-1U.W-U/;:=>S)`LTD=O*4V'^C!<[5R,':,C.<''(SWQZ]Z]+-\@ MSSA^I0HYYE6,RNMB:;2]K)JUSFP&9X'-(3JX# M%8?%TH2<)5*%1SBI+H[QC]ZNNUR?>OK^A_PHWKZ_H?\`"H:*\@[R;>OK^A_P MHWKZ_H?\*AHH`FWKZ_H?\*-Z^OZ'_"H:*`)MZ^OZ'_"E#`]#_.H*>G4_3^HH M`EHHHH`****`"BBBE97O97M:_6W:_8#E?%WA/3/&.B3:'JWVD6\T\$\/GW6?#$^@>,+'6_$`L]2U_4]7ETOX M>BSTR'2M$34[6PDN]-U?Q8EG;V:R:C/>--:;HV)6W4-ND@"0P?5E8>O>'=*\ M2V+Z;K=I%?V3LDGDRAU*RQMNCFBFADBN+:>)OFBN+6:"XC8`K+C*G;"XFMA[ M4W=TWSJ>'KX1W$\,C>5/9WFGS@0O<6SS2-O7RV'O/F1GC>O/`^8EKV6QN+SSKNQCO&:XMK:40.01M7?$TZ,X/$T>2*;49T MDE!)W232;C=O5VA&22CS2:;5Q_Y?D='XZ^&?P\^)FGZ=I/Q%\"^$O'FEZ1KF ME^)M*T[QAX>TKQ+8Z9XCT*Y2\T77]/M=8M;R"RUK2+M%N=,U2W2.]L9AYEM/ M&Q)/AWQ5^/\`XS^&?QU_9\^#V@_`'XJ?$3PQ\9[_`,8V/B+XK^$[71IO`OPA MC\+Z)%JMF_C*:YO8+JS&KRLT,$NH/I=E)!F'0[G7M="Z"OU75:6(!9)/G9L% MM@/W]O*QXZ,21A2V2I.%(7Y:PA6Y'356G+$T:<:_)0E6G3ITYU8-<\5&2M)5 M.2HXJT*DH)5;Q;)C""ES*$5)Z.223:[-I7L/5P-S,_&<`,`NT@L"H!`;.%S\ MQ.0,J=O-2*Q;!`X/?/\`+UKY/M?"_P"UHG[5FJ>*;OXH?"FY_9#G^&UO9:9\ M+HO`6JV_Q9M_B=#=R)-JTGC==3:PFT)[?>7AGAG66"=;&+2+"YMCK=S[CXQ^ M(>A>"(+1;^1KK5-0G@MM,T:W=/MMZTUQ%!YR[BWE6R^86:XE"HS+Y0)E95.; MPM;VV'I4:JQ'MJ:JN-!3$I1M(O^OT[;]?^">@ MT444A%>FN"<'.T#`XW?3)V^_)XP!U.!FG888W#&#;7]I#]OKXPSV>F?!O]GW26GO+&QFOM06!/%'Q6O] M+O()?"WAFSL([O4UM+B\TW4-3L[2[U)KK1?#EAJGB/3NW+,LQN=8VEE^74?; MXNH[J#:C3I0C[TZ^)J-J%'#TH)U*M6,OA-^SU:^)+:TN=7\007>CZ;_PF/C/Q'I'A+PE MX633-0M==U;3-0OXYOZ*_P!E+_@EAXE\2?%#0?VUO^"G/Q`C_:I_:\DL/.\/ M_#RXLM+NOV:OV;!=>7&ZUBT MB\6ZC^,?_!R]_P`$OOCKXV^(5K^WO\%K/Q;\4O!]KX,TOPM\:/`=O=:IXLU[ MX>IH-REAHGB[P'X-BLK]YO!>H6#L?&MGHEL9=&U>S/B/[#>:?K&JRZ7^K>'% M3A;+N*LNP,,VHRS#$4L51J\1SH47@\-B;1C#"IZ3\(/"WA^WL= M,TRZTSQ%=_$"SEL37ZV_%C_@TA^#LGA._N_@Q^UO\6+/X@);7<^F)\7O#?A3 MQ5X0U?5[IY95AUA?!NG^"?$.EVVHW\[27M_;7>N7D+RO=)INI7.(V_B(\$^- M?&WPR\4Z?XT^'7B_Q5\/O&>A7+2:1XH\%>(M8\+^(M(GAGF8R:?JVBW5C?Z= M*2[13_9;B-IK94LKMI+=6MQ^VOP0_P"#C[_@J=\&=.TS1-1^*G@3XWZ/ID44 M$%O\;_A]I.LZG);0`8CO?%?@^Y\">+]6E?`\V]UCQ)>7^<.+O(K]NXKX4\0J M&8TLTX&XEH8?!*AAY3R[,*\IXG%8JFU*K7EC\1AL=+,(XA2E&FL3C*?U>"5. MG2I0<4?G>3YWPW5PTLOS[+:]3%-2A[;#TXQI4+Z04,+#$T%1Y+;J$YU7[U3X M=?R`\3?`/XU>%/$OB#PEK/PO^(4FJ>&M M6T>A:1HT M';1Y-BR_V]X!\27T_B2RL(&=I4N_#_B;QA>W$?\`HL6AI.L:W'];OP=^+GPU M^.WP\\,?%?X0^,_#OQ!^'?C72K;6O#/B[PO>)?:5JMATU"SM+F)X5_,/%WBOBC&Y=A\FXLX*I9-4GBJ6(R[.(8I8N% M6O3A5GB51J4<.Z,%5HM\]+VU-PYHIQYN6+^UX+RC*J&+JXW*,\GBXTZ4Z.(P M,L/2H2A"I/GIJJD^?GI2<5S*4V^5Q7UUYU]=O`BK)>W,\P7,C-7^7] MI^(]2T\C"HFJ::I"D#:ANE8`JO(3<-W3;N4GJI(_U+?^"]?_`"B*_;7_`.Q! M\(_^K8^']?Y9L4KP7$<\>WS+>=)XB\<-"T4@:*15*.C( MSJWV_@)"5?@O.Z,4I3J\08RFE-VBY5(K^ M;F#3]`T/QA9^']2UR_N`"(++2[>ZNIV!6&%V!`_@OT?_`((__P#!7C_@HIH> MI?MJ^(O!P\67_P`65N_%VC77Q6^*FD>%?%_B_2+P&[T:3POX=UF]:/1?"!@F M2#P;IVK1>'[*STQPFBV-M97+7-Y^*WC?P9XR^&/C/Q)X!\>:%K'A'QUX'\1Z MGH'B?P[K4!L=9\/>)=!O;C3;^QO8$N)UCN;*ZMWX6::V9PL\+3QM%<2?+Y3X M-\)YO1S#"X;C7Z[Q!@>;Z]1R^%"I@,)7G.2C!PG%8BI2YX3C.I&2:?(^6[5_ M7QOB!FF#JT:]3(E2RBNH^QG7C.->M%1C)RI5%-PTBU*TDG?1+1G^S[O)8(N< M8^\R.JD#N6=.<]@2P+#&3@D?DY_P66_9L^#7[5W['EQ\)_CS^T_X._9%\`M\ M4O`/B9_BWXY3P^_A]M7T7^U4T[PU)'XE\8>!])^T:N;J66!WUQ;H-8`VUG<$ M$+Y/_P`&^?[7WB[]L+_@G;X&U3XC:A=ZW\0_@AXHU?X`^*?$>H7+W>H^*8?! MFC>']:\)^(-1N97EN)]4N?!?BCP[9:Q=74TMU?:QIVH:C*RM=B-/"?\`@Z15 M5_X)=W6%7][^T)\'0V55L;#XG9<%@3U7!!)!5G4C#MG\DR#)\PR[Q#P&0+%O M`9C@>)GB%3CB:-+$Q=*::G"<(U(VE=*HHV:7W.-S'"8OA? M&9F\.\1A<1E=;$/#5'R.K3E3C^[E*+3BE*Z;3O;5:Z'Y!?LP_P#!&W_@G)\. MOVEOV=_B!X-_X+7?LY?%#Q?X$^./PL\:>%_AKH^6[U^\T^+2(9;31M5NHI+U?+LY"YCD_NN1MD2G;CY%^4!GV87)4 M?>8X''`W''3T_P`@_P#X)\D#]OG]B'Y(B?\`AK7]G10?*C&%?XP^#(V&T*%. M5<\E2PP`I"EPW^O'X?XS"XS`8_Z MAEU#*Z5+&48RP]*K6KJHW!.4G*LVHWZ*+]>Z^.O%G_!1#]@WP'XH\0>"O&_[ M9O[+_A'QAX4U:]T'Q-X7\2?'7X;:+K_A_6],N'M]0TG6-&U'Q';WUAJ%G<1O M!EU/QE9:G+X>LDTBY@FMK\W-_']EN(I()=LJLE?Y7__ M``554#_@I7^WA@`EOVK?C>261).3X\UDDCS%;';Y5P.!D$\URW@3Q=^U]^U1 M\,O@Q^P=\'/#7Q"^)'@WP#KWC'Q1X6^$7PWTS5M3.N>*_'/B"35=7\;^-XK* MX:$P:8E[8Z3INLZX+7POX6L`;J*XM;O5+R\;Z!>!&!GDV49I3XF5&EBX87%9 ML\9AZ5*A@L'7P7UBJZ52W/7K*KR4J?M/9Q]YS<^6'++QUXDXB&-QF#GE2K5: M=;%4L'##SJSG5G0E)4U6@](QERKF5%RDT[)<[/\`4$^"7_!1[]A?]I'XB)\) MO@-^U'\(_BO\1I=+U+7+;PGX,\2)JNIWFCZ,%;5=2L3%"+6_L;!70W5S:7$T M48=,OEU!^UMZKE2P)[`$DG`)/.6/`!)QG@$GOC^%#_@A1_P3`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`\)K+P?X`N?$NN7U_<_!OXC:TKV_A2V\, MW>H3;E\">,-;O8_#NL^'76*TTK59M$UK2[?3YX=5L=0_T-[=BX)/W@%R5'R` MLB/@')W8##YAP1V!R!^2\9\'YEP5FJRW,.2K2K4HXC`8NG=0Q>$DW&-3D=IT MJD9QE3J4IQC*#BFKTY4YS^YX?SS#9_E\,;AU[.=W&OAY?'AYIZ1?>,E:4)*Z M<7TV5BBBBOD3VPHHHH`****`"BBB@!"JDY*@GU(!/'(Z^_-JUT?AY%6EYX=^R1LM[>S/&T%X MMZR[T$:H59"C=MFSYL]%'>0R3O;)-"T\`0SVZ2))-$LHS"\B!Q)"C@-L:6,> M6G/R)SC/RCG`(&>.<`D#/8FO-7^%?A.XUO5==U&RFU>]U9X&+Z MG=3W8TM(&258M&D:99M/`N(XYD>)B\.TPVYCB=@/268@X&.G^-.'(!]0*<93 M@^:$YTY;.4'RR:W<;K5)];-/LT`M%%%(#\7_`/@M)_P4VMO^"=?[.-J?`T,F MN?M,_&^76O`W[/GA^&"PU)M.UZ.RCBU;XAZCHUU*9=6TCP1+J&EI!IEO:7IU MWQ1J_AW1)83I-QKE[IO"_P#!(/\`X);W'[+^@2?M;_M0R:A\1_\`@H-^T)87 M7C#XQ_$/QO>)KWB;X>Q^,(;2ZN?AMHU_"'TV#5+2"*VM?&^NZ>K#5=2MVT31 M[B/PAI.EV`_P#@X3_9Y\:?M&?;(O@'\-/%G[(?B'P_/K\- MY<^&;7X6Z3KWAWQ'XWU6RLC<_8I[71_&#>,[GQ.EO#++)'87#ZG%-;+IL=K_ M`'G^$?&'A#QWX>TKQ7X(\2^'?%OAG6K2&^TC7_"VLZ9KNAZE:7$22Q7-AJFC MW5YIU[`\3(T&.!^&\)@%S_ZY8&6=9WFM%24L11= M7DPF1RJK6E1P\(^TQF'C)1Q-64'47)%0?QV75Z6;\0YIB*[]W),1#!8'"57% MJG65*+Q&-47I-U).,:4FGR6;C[SYGT0^0G[[$+G@G@8`P#P>H.>F`1UR:_GW M^(__``*?AYXT\4>!?$L5M\([6YLX]?\&^( M-1\.:VMM,_C"VE>"'5M+NHX7ECM)VV(SP1-N0?O7KWBGPSX;2%O$/B30_#ZW M;&*VDUG5--TU9Y,-^[MFU"ZMA/-P3Y40E8XX3FO\ZG_@XD_X)I?$7]F;]JOX M@?M8^$O#]_KW[.?[1OB:Y\;W_BC3-.FFT_X9_%+7VCN/&'A3Q3<6ZO;:3;>+ M==^V^,/#.HW2QV^K3ZOJVE6]U#-H8MKS'PMX?X8XCSVMDW$E3$8=XK#4]+1Z:(_HL^"?@+_@B'_P7.O?C+XR\'?LPVU[XY\`ZKX=E^(7B MN\\+ZE\!OB-J-YXTM-:FT?6YM2^%_C#3[_Q4DUQH.I+/J'B/[7;FZMWAD2XD M26:+YR_:9_X-._V:/%FFSZG^RK\?--$`R8AJ,^K^*FA1\FPN'*(_P#'=^Q#^WG^T;_P3Z^+C?%O]G/Q=::+ MJFJ:?#HGC'PKKND'Q%X+\>^'8+IKN/1/%6@>?8M6,*6)IXG"XZ-15(RJJ52G]64Y3IK2*FHJ7Q&%XC MX6S;`2_UARV"S-1FZM3#8/EG6>C4J5:@U)..D9<^KNEKJ?SX_M1?LV?%']CK MX^_$7]G#XSZ79:1\0_ACKD>EZFNDWT=_HVJZ;J&GV&N^&O$VA7Z>4\^B^*?# M>K:/X@TC[3#8ZK'9ZE##J>F:=J,=S96_]6__``:,_&KQ?%XI_:X_9ZO+^ZN_ M`-KX:\#?%_0M(+,UAX?\3_VO=^$_$USIL$KN]L?$FER^&(KV.-S'+)X8L9)% M\^2YGF_D6^+OQ?\`B9^T!\3?%OQ?^,/C/6OB)\3?'^LMJOBGQ7KEPMSJ.LZD M\<-K#$L42V=M:V=E:6]KINCZ-96]EI^C:9:66DZ;:V=E9V\,?]Y7_!L)_P`$ M_OB?^S/\$_BS^TQ\:O#5SX0\4?M+#P-:_#KPQK$4EIXETGX4^%(]UBXM[,:P+5/J/%G$T\'X:8G"Y[7P]3. M,8LKPT/8)PI5\YP];!5\;6PM.5I4J/[K$35H*4Z7N2LINWB<%PE6XOC6RO#3 MIX&%7%S=27,G#`SP^(I4*.(C]NK"4J,6YMR4TG\2/TC_`."]8_XU$?MK'.<^ M`?"(_P#,K^`#G]*_RS[>&.ZO+2TFR8;J_M[6Y3:/WEM=21PS1!\@J)DW+(0, M[`8QD2L4_P!2_P#X+UE1_P`$B?VU4#`@>`?"/(Y&3\5_`!R"22>#@G)Y//6O M\M/3R/[5T_D<:KIY/(X`N5R3Z`=R>!WKQO`52CP1GLK^]_;F/O);)K(\OL]M M&I2=K]7\CO\`$]K_`%ARN*>CP6%C+RC+,:\6UM;W*DM>CUZ'^T%X;TRQTOPQ MX=TC3H$L]-TO0]$L;&SA&V&UM+"RM8K2U@4DE8(88(H44DL(U`);O_EH?\%R M+6&S_P""LG[;4,$4<2O\3=#NG6)=JM<7OPV\#WEW,0>2]Q=3S7$A/_+25@,@ M`G_4^THC^R=,Y'_(/L/TM(\_EWK_`"R_^"Z7S?\`!6G]M@K\P/Q&\,X(Y!_X MM9X![BO@_`"\^,L_A+5/),54:2WFLWP2N^K=FUK=VZGTOB7"/]@Y)",D#(_X4[\&^1ZCD M<].1ZBO:_P#@Z2(/_!+N8`Y/_#0OP@'XA?%1(_`_^K]2_D[;>1_!]_P`$^O\`D_G]B'_L[;]G+_U< MG@FO]?%/NG_<7_T"O\@[_@GT"/V^OV(W](O_D=\-_]BK$?^K!'#X5_[AFW_8=1_P#343_)1_X* MK?\`*2O]N_\`[.M^-W_J=ZQ7]D?_``:G_!KX>^'_`-ACX@_&S3/#6G0_$OXD M_''Q?X8\6>+V0OK%]X6\":=X>'A?PVDS#;#I&E:AK>OZM!!$(_,OM/\`@F%*#P1^ MT9\7\CN,VW@PC(ZC(Y%?:^*E2K'PAR6,:DXJ\9>T:4H]5)=&MGJM3^CDID!>WU]\\C' M/YBO\LC_`(+QZGXIU+_@K-^V0/%CW!N['QKX0T[24F.!'X6L_A5X#B\*)&GE MQ[(3H1LY(6&\R[Y'9SA7D_U.J_B6_P"#GO\`X)G>,M8\6Z9_P4.^#N@:SXIT M^\T30O`O[1/A[0M*^WWOAU/"]HMEX/\`BS*EHAO)]#;18G\)^-+^6-K70;70 M_"E]_HMGJ&HZC8?DO@CGF`R/C"5/&SA0>:Y9B,LPF(:@E3Q-2K0JTZX\?0'XDS_"CPM\/==L/ M^%@P>'M'98M."5Q*5^T/B_P"&O^#F MSX[_``U\7?"'XN>!/VK?'WPV\>Z8VA^+O"&L^`OA1%INN:7-/;RFTNI[#PY9 M7]NB745M=^=97EK<(;92)T7=7P__`,$H?^"NGQ;_`."7?C;QA/H7A2T^+OP5 M^)@TZ^\?_"?4-7D\,2MK6BK-;Z3XO\*>*$T_Q`/#_B*VL)Y-/O[2ZTC4M.UG M1I[3^U(;:73M)UA?U7_;?_X.F_BO\;OA3>_#;]DKX/Z_^S5XCUYK*/6?C%J7 MCO3_`!5XUTBUM)UNK_1_`VDZ9X8M--TZXU)8%L+OQ;>7\]Y8Z?+>_P!FZ+#J M$UK=V_[CGZXPAQ4XY7P)P;F.!Q&)H5J'$^)PE%UZ%6$5*K/'5H2==8ZC*#E! M1YJE51C5BH5+17YYEU;(X9/3>+XGSK"U*-&-&>5T<0I1<(0A"<*5"IRTY4JE M[A_L3?'S3];T.^LM;TB^30]+CGL=8T MNYCU"PO5,^KB,/:WT$5Q^\RC>7@EU()_U5?"-SJ5WX;T2YUB)H=7N-)TV?5( M65%,&HR6%LUY;OL9E,D-P9(W*DKE2`<`"OX!/^"-_P`;O^"O/_!0S]J_P7I= MQ^UW^T/>?LY?"SQ+X?\`%W[0GB6_\3I8Z(_AK3]3-]#\.+.[@LXFO]?^(#6( MT4:9I\L%_IFC3:[K$TUO;Z9!+F\/3QGU3EHXV>+2J*I*-"-: MG3F^>$:O-;DJ19]YX?8/`T<)C<;E]/-*>&QM6E!/,%04JTJ*DXUJ<:,Y.-.U M24.=WB^2,=XW=VBBBOQ,_1`HHHH`****`"BBB@`HHHH`*YFU\+:+I_B#5_%% MK91P:OK5M:VVH7OGSAKA+,*ENC1%_(0``9D51(3@$]1734C#<",D9&,C&?U! M'Z4U*4;\LG&,ERS2^U&Z=G9K2Z3MUL!\Q_$;XAZ]JXU?1?!MOJ]CHFBWR:9X MT\76MA)+)IL?F>3>PZ;:LJ74S6H9C+-%#*#&6=1Y8WU;^$WB+RO$NH^"M&UH M>,_"6GZ/;:CI/B.(,9M*B'M7CN;7 M3[BTB2[UNZM;C$]WJT5@]M;_`&"\,OV:SB^U9=9`-K.55^^B\/5HSPZI0HJ$ M)J$W*[=2?*XS247.51._+%)Q5[./+%-A]+4445YX'@_QN_9H^`_[27A<^#/C M[\'OAU\8/#1^T^1IGC_PKH_B-=+DNXO)EO=#N-0M9KK0M4\LE?[4T2?3]25B MLL5Y&Z`GXH\#_P#!%;_@F-\.M:;7?"'[)7@S1;U[C[2\0\5?$O4=(F&PU27/+#4,= MB:.'3Y5%VHTJD(:VN[IN[>NIRU,#@:U15JV"PE6JHJ*J5<-1G.R=T^:4'*Z? MG;R/(?`?P&^#?PL4#X8?"GX:_#EBOES/X*\$>'?#99656D#L,UW_B+PSH/BS1K_`,.>)M$TGQ'X>U>WELM8T/7=.LM6TC5+ M&92LMGJ&F:A#<6-[;3#"RP75O-"Z\,AX(WZ*XG.HY*;JU74B^:-1U:DJD9)\ MRDJDI.:DI:IWNGJCHC"G"'LX4Z<8-.+A&G",6GT:22:[7O;;8_"WXR_\&Y__ M``2O^,GC#4?&[_`S6_AEJNK7$UUJ6G_"#X@>)/`WA:YGG^:1[3P;%- MR<9`PZXSD'L?Z+**^IH\=<9X>E3H4N*<\5.DN6G&68XB?+%62BG*;=DDDE>R M6AY%3AW(*LG.IDV6RDVVV\+2U;=V[))7;W>[ZGYG[%NJCQ1\ M'?@!HFH>/4DADM/B+\3KZ\^)WC323`8VA/AW4_%[ZE:^%'B>-9#-X6L-&N;E MU1KR:>1?,K]/8X2@/R\DY)RF3R>NQ5!..2Y!=B<,QP*M45X6/S/,CA*2_Y=8>G" ME!V5ES*,4VUO=N]];ZN_E_Q@^#GPU^/OPV\5?"#XQ>#-'^(/PU\;6EK8>*O! MVO))+I&MVEEJ5EJ]I#>1P302E;?4].L;V+9*A6>VB8D@%3^?L/\`P1-_X)7P MW'VB/]B#X*0R"2*1673M9DV20NSQ2*)=8=!)&["1&\O*2(I!(P5_5*BM,'G6 M/Q6%H5:DHPA*I4I4*L(3FX4X1I35HSK4*562CJU%2G&344Y.22LN9M]2C':B.*.%(E2.*. M.*-%;:D:(FP*,!@0@`"JR,IP`1CD?G]\5O\`@E'_`,$\?CE\1/%GQ9^+W[)G MPJ\?_$CQM?P:EXI\8>(+#49]7UV]MK&STJWNKZ2#4[>$RQZ;I]E;*(X8D5+= M`%R"3^A]%88+,,QRRI*MEV88[`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``3=^*GC?Q=\2_B-^Q[\(O%GCSQYXAU;Q9XO\3:KIVIR M:AKWB/7;V;4-6U6\:+5HHC%+>6WTS^WM82WBU+5`MQ//(MS?1VEM]I&]HRT*> M6%PQ;WFBMJ^2Z9^5/[2/_!%/_@FI^U5K5QXJ^*G[+W@^R\97^,/AC?: MW\(]?U&YN)%EN+G6)OAUJ/AVQUZ[F=5:6\UO3]0NI6W%Y,L<^!?#W_@W(_X) M.?#[Q+8^)D_9VU3QK35*OMIY7@)5>9S>#_"W@+PEHRM%I?A;P7H&E>%_#FG0,=QCL-$T6"RTR MT#/\TGE6B[\`G,VZ8]TJD'D=O;VJ2BOG9.4YSJ3E*=2I)SG.204444BPHHHH`****`"BBB@`HH MHH`****`"N4\8>&!XLT.?1FO9+#SI].N%GB02;)-.U.TU.+,99=P:2S1'!89 A5CG-=713C*4)0G%M2A*,XM=)1:DGYZK9Z,`HHHI`?__9 ` end EX-99.02 5 mar2404_ex9902.htm EX-99.02

Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com

 

For immediate release
7:00 am (ET) 12:00 noon (GMT)

 

FIRST APPROVAL FOR FOSRENOL®

New Medication for Patients with End Stage Renal Disease Approved in Europe

Basingstoke, UK – 24 March 2004 – Shire Pharmaceuticals Group plc (LSE SHP, NASDAQ: SHPGY, TSX: SHQ) announced that the Swedish authorities have granted the first European regulatory approval for FOSRENOL® (lanthanum carbonate). FOSRENOL is a new medicine that helps control phosphate levels in patients who require dialysis for severe kidney disease. Sweden will be the reference member state in the EU Mutual Recognition Procedure for FOSRENOL. This is the first step in securing marketing approval throughout Europe. Assuming a positive response from other regulatory authorities, FOSRENOL should be available in other countries in the European Union during the second half of the year.

FOSRENOL is a treatment for high phosphate levels in the blood (hyperphosphataemia) that occurs as a result of chronic kidney failure. Estimates show there are approximately 225,000 dialysis patients in Europe1. Even with a low-phosphate diet, as many as 80% of dialysis patients develop hyperphosphataemia1 and need treatment with a phosphate binder, such as FOSRENOL. Without effective treatment, hyperphosphataemia can lead to renal osteodystrophy, a bone disease that can cause pain, skeletal deformities, and bone fractures. Recent research also suggests that hyperphosphataemia is associated with the development of cardiovascular disease, which accounts for nearly 50% of all deaths in dialysis patients2.

Matthew Emmens, Chief Executive of Shire, said: “This is an important milestone for Shire and reflects confidence in our ability to successfully develop the projects in our pipeline. As was said at our recent results presentation, we have five more drugs in registration and the potential for 11 product launches by 2007. Our goal will be to launch FOSRENOL throughout Europe by year-end. In launching FOSRENOL, we will make full use of our European infrastructure and build the platform for global success. We are also working with the FDA to gain marketing approval in the US, the world’s largest pharmaceuticals market.”

Dr Wilson Totten, Chief Scientific Officer of Shire, said: “This first approval for FOSRENOL in Europe represents an important milestone for Shire. For clinicians and patients alike FOSRENOL will, we believe, represent a milestone as an effective and well-tolerated alternative to current therapies.”


Submissions have also been made by Shire to gain marketing approvals for FOSRENOL in the United States where estimates indicate there are approximately 270,0001,3 dialysis patients. Shire recently confirmed its out-licensing of the rights to develop, market and sell FOSRENOL in Japan to Bayer Yakuhin Ltd.

- ENDS -

A photo will be available on our website under “News & Media > Media Centre > Shire Pictures & Logos”.

For further information please contact:    
     
Investor Relations    
     
Cléa Rosenfeld +44 1256 894 160  
     
Media    
     
Jessica Mann +44 1256 894 280  
     

Notes to editors: Following the recent agreement with AnorMED Inc., Shire now holds full patent rights to develop, manufacture, use and sell FOSRENOL in both the US and Europe.

Hyperphosphataemia and its consequences
Chronic kidney failure is complicated by hyperphosphataemia – high phosphate levels in the blood – caused by the inability of the kidneys (and dialysis) to filter out excess phosphate from food. Even with a low-phosphate diet as many as 80% of Europe’s 225,000 and the United States’ 269,000 dialysis patients develop hyperphosphataemia1,3 and need treatment with a phosphate-binder. The most well-known consequences of hyperphosphataemia are a range of bone diseases which can cause bone pain, skeletal deformities and fractures. Hyperphosphataemia is also associated with the development of cardiovascular disease, which accounts for nearly 50% of all deaths in dialysis patients2. Ironically, currently available phosphate binders – although they help control phosphate levels – can worsen these complications. Aluminium-based phosphate binders are associated with severe bone toxicity while calcium-based binders contribute to cardiovascular disease by promoting the deposition of hard calcium deposits (calcification) in the heart and blood vessels.

References:
Numbers of patients on dialysis broadly equates to patients with end stage kidney disease. Source: Market Research, Insight International, Dec 01/Jan 02
2. Davies MR, Hruska K. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int. 2001 Aug; 60(2): 472-9

1.3. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002, page 44.

Lanthanum carbonate (FOSRENOL®)
FOSRENOL works by binding to dietary phosphate in the GI tract; once bound, the FOSRENOL/phosphate complex cannot pass through the intestinal lining into the blood stream and is eliminated from the body. As a consequence, overall phosphate absorption from the diet is decreased significantly. Shire has conducted an extensive clinical research programme for FOSRENOL involving almost 1750 patients, some of whom have been treated for 36 months or more. This programme has demonstrated that FOSRENOL is an effective phosphate binder with a proven safety profile for long-term use.

Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.


For further information on Shire, please visit the Company’s website: www.shire.com

THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialise, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialisation, the impact of competitive products, including, but not limited to, the impact on Shire’s Attention Deficit Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise, government regulation and approval, including but not limited to the expected product approval dates of lanthanum carbonate (FOSRENOL®), METHYPATCH®, XAGRID® and the adult indication for ADDERALL XR®, the implementation of the planned reorganisation and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission.

 


GRAPHIC 6 item1x7x1.jpg GRAPHIC begin 644 item1x7x1.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"M`3$#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@!#TZ$\C@'!ZCOD=.IYY''/2O+?%\7B MFRUL>)AKTUGX*\-Z%?:OJ&BZGW<>L2Z)K<<,6 MG:UI>L&^NK+4EBN9EAU"&54:!TS(D+2Q^=]&+XK\.C7U\*?VK`_B$VAO3IJ+ M<23+;KU>218F@A7S%?5O#VFWTEU:65[#&YVPV$5K$)&3S%>38P\HT+QB?!NH:I8> M&-&L]6$%SJ?]K^+_`!=?7UAJ7BC6M)Q)KFG:;J#+<6UO-`3NT[2KRY3[3%E8 MT)#,>VI1I8ARJ86FJ247)TW)*R323UTMV5W*3=_A3D!]A2AB`5W$J<[5;&X= MQ@L@/MET`/))'!\?\46OB#PM+JOC1=>\2:MH6E:>+W_A#HKJV7==)>;16%$EAU'1I)X8K]%N[A9`RDI\V3],65_97\0ELKNWO(U)1 MI+>9)T5UX96>,LH;O@D$C#`$$&O%?B3\/;.+08_^$2T*.SMFUBQO/%6G>&X; M;3M5U[0K>0M=6-O.B*TDJEA/%:EA%*Z8:-L`#!^%/A75;#Q)#K-I:C1_"EOH MUUIEM;3V$FB:SK,[W`>TG\0Z,JBT_M73;>%X'U6#Y-1B>.;S6EDFC7TZ_P!5 MQ5+V\8T\/.G3LJ<8Q4)Y$;F%)I(\NL32!5?Q#/H5C/XJL[*PUUXR;^TT^=KJVA<,0H63+@L4"LZQR31AC\LAR0 M-\,K=#G'7@\>QXX//0\UBZ_I=QK&D:AI5IJU[H=Q>6[1PZKI_E_;K*0D%9H/ M.1HVVX^8$9QD9!-5+S5+'P?H!O=74 M^`D442[RVU5)!-4DY-1BG*3T44KMMNR27FVEZL#I2R@X.<\#H3]XX'(&.I&? M3J<"G5\H0_%#QSXDO-9\:^'8M*@\*>$HW^U>&;^]@MM2U?3U,5S=ZG.LG[VW MNH8(`=/0XC=4ZBT<9N.MDFM&N:Z:`VZ***YP"B MBB@`HHHH`****`"OF7XF_`GQSX_^+OPP^(NE?M#_`!A^'_@WP/%JJ>+/@WX- MU#P]IW@WXH3S2Q3:'<>(=2;1)/%6FKI4XG>^ATC7HEUK3VAT]DT]X);B\^FJ M0@'MZ?I_G]3ZTX3J4I\]-QNH2C:48S34TXRTFI)24?@FDI1D[III-)JZ:NTF MFG9V=GHQ:***0PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`$8$C M@X.0?R[?C7D7B;X>:-&GB#7K2RU._DN;.\NKSPG#>LV@Z_?B$;'NM+>WD#7< MH"HUQ:20W91%C1VSMKUZD*@]1GIP2<<9[=._7OQGH,53E*G;E;MHGJ[M+6UU M9^6Z=KZ@?%*>+?$T-WI,NDBXD\;WUE80V/AGPO?7$F@Z9:V\L$:34;-,L^Q]E#('/)KPO]HZ?X\V'P3^ M)%_^S-I7P_USXZ6WAV^G^'.D_$Z\U2Q\%WNO1AFABU2?2(#=/<&`R?V;;7%S MI^EW>J+9VVJZSHFFRW>KVG<>%O'UAXGNIM-^QWVCZI!IMEJYL=02VD\[2M1" M"SU&ROK&YO-/O+:5G"[H;ARK$*PS7=%1(@#@$':Q'.-RD,".AX8`CZ5P1@\- M6IQJT(U/92A45.O[\)\K349*,HR<)7U49)-75^R:OU:]'8Y;PE>>(3X9\/OX MTM=+LO%TVBZ1)XGL_#\UW?:%9>(FTJU;7+71[V\L["\N=)BU9+^+3;N\LK2> MZM4MY9H()KB.`]2LBL0!GD$]NWKS]?R-?,G[3/[/FM_'_1/`FC>'_CE\8/@3 M-X)^)G@OXBW6J?"'6K/2KKQA9^%-474+KP-XICU#2]1@OO#&O1QJM[:!EB^V M165Y?6FI6UJ^F:AZ3XB^,GPL\&>._`7PT\6?$7PEX>^(7Q3N-9A^'/@C6=;T MZP\2>-)/#EB-0UY/#.DS3)?ZFFE61^TWAAAE$3,D1GW.L9KV;G*FJ%ZM2H\1 M4JX>E0K2>'A32FG=)ITW%SGS7<:=.#4FM&-+\%_P#U6L?6]!TGQ%:166LV%O MJ-K#>6M_';W*[HQ=6UM=*U6QU$Z/X@LA`UYH6JB MSGF.GZS:+ M>BN%TFDW9O9=7Z+J>2_%W0?`$-O::[XA\,W>MZR\]MI6DZ?HYNX[K6;DJ9+; M3[E+,)'-:0K&7;[0"(H$,<&658JJ^$/&7BKP]-::5\1M.T+PWIU]#>W>CSPZ MEH6F66B6L`B%EH,MC-.MU<7*`M&EQ"&C+`^>8R4!]Z>.&91)M67^.-P!)M;8 MRJZ9RN0K,%(_O-C[QS\X>+?`VN7?CG5M>GTFXUI[_P#LH^%[]X;;4](TBW@M MY[;5M"U_1+R^MW&FZJ98UGN[%)[B)GCNK4V\L$A?LHUH5H+#5Y7]FI M$9-)=1U+0I;74-&T719-2Q*EK(TD$U M_9Z,TX@NTL(YY--CB"^6T*-L^C;"\AO[.WO()DG@NH(KJ">,DQS6\ZB6">,E M$)BEB9'0E0<'!)()KFJT:E&;C-7BW>E42:52GLII=+M2T\K[-`7:*.O2BLP" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@!"H.,]O\XKAO&O@O_A*DTR[M-0_LG7M!NY+W1=3-LE]!!)/"UO6EU"Q6>-I$D&`898F&ZNZHI0O2J.K3TJ-K7O:R5[WTLMMFKJVH'F M/@;X;Z;X*N;G5O,2;6]6L[2ROWMA);Z7!Y!#O%I&GS2W!L+*65%D%H)Y$A** M(\!FKTX=!CTKF_%>CWVO:-<:7INMWOAZ[N&B\O5;!87N8/+E21E59E8%954H MQ7#`'.<<5>-];:=%96M]J$"32&.RBEO)HH)KVZ6/Y1&C;%EGF5&D98P`7)$8 M^ZM7.O)?%GP/^$GC3Q[\/?BIXO\`AYX0 M\1?$;X47&K3_``W\;:KH6GWOB;P7-K^GR:5JQT+5YX'NK2.^M)Y4E@C9+?S& M%V(/MJBX'K*'<,GGG_`TXC/^1_6HC*O3E.=&M.E-PG3C.FY0DJ=6+IU:J^*M8^)%AHU[KMA\-?`7]C:O=:EJWA73?!T'B'Q2WC*:TTQ]/M-9U70] M.TGPQ?:OH%]')JLU_'':?E#_`,$^/B[\'?@-\W_``QE\6?C%K_CS]JK MQ;/\-?VX_@1\5]?\-^*9]+Q1K%G-::P-1_M7E\-:`=9F\3'1M-/B-]+&C-KJV%FFMOHT= MTU^FC?VPD`U(:6+]C>+8_:3;+=LTZQ"1F)_"#]M#X.?M"_'OX[^-/V>_V,OV M=O!/[).HZAX;L-=^._\`P4GUCX>^"/#'BG4=!\307LMOX/\`@IXI\&L/'GB3 M7]:NM-N+/QCJMQK&F:CH5C#=Z=J']DVNKZ1X@U3]*X;SS*I9;5X?>3X;`T*V M"J2S;,L1C:4J.,JNC7P\\3F-)X7ZS7PV#G5PV,P."P7M<4L71A&A%3J<\?*Q M="5.2K?6*LI^T@Z=.,92Y$FG)1;FDDVES.5EHWJKG[[VI4P1%""C*64@`!@Q M+;@%)7#9R,$@@YR:E90<'&2N<=NO4$X/!P">.H'I7X1_L0_\%8OAG<7EO^S= M^TE^T1\+_B+\6O#_`,2;GX.>'OC?\(/A[\9]/^`_C?4+&VM[/PMH_B+XL^.M M&N/![?&#Q4UM?W5[8Z9XDNO#^LZCO3P]K6LR/YLW[KQ.Q#-(Z;0<`\#!`);/ MZ$9`.,DU\)F648_)L1]2Q^&Q%)I2=#$5<+B,+0QM&E*$8XK"QQ5*C5G0K%+O5M7.AKIL$FL36WB!A:ZEH7V]Y;>"YTJY>Z:1X[T/*S!6,AE M5'6#1O&WC#1O&,NB/%!<>';;7?#VAZ=X&=:B6TT'58[P$W3&W>W M\O4EFC:P+R*+:ZE8[1]):EI]GJ=E=6-_;Q7=I=P/;W-M.B2130RC;(CHY52" MI/.X%2`R$,!7#>&/A_H7A'4+_5[6]U2YFETZ+3EDU;47O(M/TRVN6O4MK9G5 M3%!%+M9=[RLJQ*!*%%3'$0G1JPKIRG&GRX>R32?->[VY=Y7:3;[ZFAZ'YF!T M`XXW-M'L.AP>W3K3T<."0",'!!ZYP#_6OEOQC\5;SQ+JT'A3P7JJZ#IWN0JQ70R%:WO"(S%=VQ4B*56:-W7&)G@L12HPJU8J M$I).5*3?M8)V5YI)P5VU[L9RDN97BDP/6:*3(SC(SUQGG'KBEKE`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"N>UGPMH>OR:?-J^FVE_-I5]%J6G27,;N;2\A8F.9-LL8+("=H;*J<'!*BN MAHH`Y2X\4V.G^(=*\*O9ZG)=ZG97-W#=P64LNFP1VK;/+N;M6]C;S7=U+%;VUO%)-<7$T@C@@BB1I'DEE8;4C55)9FP!P!EB%, MXC0,6`.2,?>8C&<\`D@$]R`"P`!)``'@OQ"\'_$3QUJ%]HJW^GZ#X.M;-)[* M2V:6:ZUJ_P`[XK34HXI%>&VCN(X_,2%>C!T>5E7&L(1J2C'F5)*#=2=; M2$;98B&RI.VLOXI>`[7XG?#CQ]\-]1U&_P!(L/B%X,\4^![W5M'N9+/6-,M/ M%>AW^A76H:5"00=.I2J2?PSA47(W"<6G[LXW MC>]G9/9I-+83BI73U3BXM/5-/>Z>E^E_N9_(O\1O^"5^G_LZ?#GX5>%OV@OB M=\)/V=?@3X=^(/P'^'?C#XJ?`V;XA7^I?M?:EHGQ&TRY^%=M\9/@/J/A27PM M\/?B@EW:6]Q/\OZY\2?@'\3O!7@[5/B#X7T7XV: M'J_AJR\.7^E_$OPII.L7_A'QAX'\1R:0\MAW[27Q5@N;[]G+XB_#GX;7$'[,<5_KWA_POX9T3P[I7C:_?6/A M[K7Q0\4;M;TZQNK::R\5:1J;27.J_HV79QA>+Z>)P.=QIXO.Z[QTLO=:C4P] M.G7KNE6Q688?$X24'/$QH4,17K4,53Q*K3P.!RW`TXT<55IP\FI2J8.:GA[J MA%WJ);)75H..TN9R4.;=NTC"`DD!54\_*2@"% MC\O%/FC\U&C(1D965E==RMNX*NI^5XV4NKJ1SD8]1_/=_P`$+?&7[17CSX?6 MGC.[\=>*/''[*FL?#A=)B'Q>^(EY\4/BCX4_:H\%^*O^$=^*=OX2\;ZKIT>K M^(/@?XWTWRO&7A,:KKFO2Z!=W2:%9RZ:D%YI=K^]&H>/?!&C>)-#\&ZUXS\* M:3XO\46>K:CX9\*:GXBT>P\2>(M/T`6S:[?:%H5U>0ZIJ]GHJWMF=6NM/M;B M#31=VQO'A$\6_P"#S;*JV49EBLNJ5J>)J8>512G04K)4TW54X22E3E1Y9NI& M7-R17,YM>\>C1KQK4HU?@4^6T9->ZY**4;[2;D]+=7R[JQQ'CGP'=ZAX4_X0 MWP?I^AZ-IFK:@1JLH@5%L;>1OM,^H65DBB*:[EFCVM(Y\[YL(X`X\DL/&>G> M!&UJT\*^$/#FFZ/83:G83ZSJYFLY_&6M^'55[RRBNX+=X+#49?->6UM]0-Q' M<9Q#M9F-?7>8CG:R$_,`59<@D$$*0<@\'.W!X)ZYKQ[Q3\-M+9/$>M:;I%WK M%_J5K=7=UX3?4Q;>'_$NHF/:CWUK+;4EMOKT[]/ZU.KA^('AU-(\.:SJM_ M::2OBI-/72;>ZE*W%Q<:BD;P6JH%)9\R*K.H*?Q!MHKN48.H=2"&&00201[$ M@?RKXTO-2NO"OBO1[WQ-I&GZ_P".7M-/$5M-R"STBR2;[)>1Q M7;R)L.H3A+82XPPF6(GZ8\$^*F\5:0U[+:'3[VSOKW2M6LOM,-Y%:ZC92QB1 M;:\B58[RS=)DDAN(U5=I\LJKHX5XG"RI+F@UR.TE+FC)B3LN9637M+1C- MZQ25DP[6BD!!Z$'@'@YX/0_0]O6EKENN^^J\UW`****`"BBB@`HHJ*>>"U@F MN;F:*WMK>*2>XN)Y$A@@@A0R2S32R%8XHHHU9Y)'941%+,0H)H`EHKX`_P"' ML7_!++_I)9^P!_XF1^SK_P#/&KU/PK^W?^P]X[^*S?`CP1^V5^RGXR^."ZQX ME\/-\&O"O[0_PB\0_%9=?\&6NK7OC#0V^'>D>,+SQ>-8\*66@ZY=^)=,.CB] MT*UT75KC5(+6+3KQX0#ZLHKX/C_X*F_\$QIM+O->-/!'PW\?_M=?LP>!OB)\3-*\*:[\./`7C'X^_"GPSXT M^(&B>.[Z73/`^L^"/"VM>+++7/%>E>,M2AFT_P`*:CH-C?VGB&^BEM-(FO+B M-XP`?3U%?`'_``]B_P""67_22S]@#_Q,C]G7_P">-7LO@C]M7]C;XF?#WQY\ M7/AO^UK^S+\0?A1\++>XNOB=\3O!'QY^%GBOX>_#BUM+)-2N[GQYXTT'Q5?^ M&_"%O:Z=)'?W$WB#4M.CALI$NI&6!ED(!]-45\+S?\%0_P#@F?;:%IOBFX_X M*(_L+0>&=9U?6]`TCQ'-^UO\`8M"U77?#5GH&H^(]$TW5W^("Z??:OH&G^*_ M"U]K>FVMQ+>:59^)=`NKZ&"#6=.>Y]:^!_[8O[(O[3>IZ[HO[-O[4_[./[0> ML^%K"UU3Q-I/P/\`CA\,OBQJ?AW3+ZX>TLM1UVP\!^)]?NM(L+RZCDMK6[U" M*WM[BX1X89'D5E`!]'45X^_[0OP!C^,B?LZR?''X/Q_M!2Z`/%D?P*?XF>"T M^,DGA9HFF7Q*GPQ;6QXV?0#"K2C65T,Z<8E:07.P$U+IGQ^^!&M?%?6O@-H_ MQK^$FK?'+PWI,6O^(O@QIGQ(\'7_`,5]!T*<*T&M:U\.K769?%^EZ3,KH8M2 MOM'@LY`ZE)F##(!ZW17DOQD^/OP)_9T\+1>.?V@_C5\)?@3X*GU(/&'QD M^(_@[X8>%IM6N@QM=,B\0>-M9T/29-1N0CF"R2[-S,$8QQ,%./3["_L=5L;+ M5-+O;34M,U*TMK_3M1L+F&\L;^QO(4N+2]LKNW>2WNK2ZMY(Y[:Y@DDAGAD2 M6)V1E8@%NBBB@`HHHH`****`"BBB@`ICG`SG!R,9S@GTP",Y&>O'?M3Z0@'J M`><\C/(Z'GO2:NK7:\UO\@/#/&/@:RN;O7O&GCR_E\2:#H=C=ZAHOAMHGM+# M2;:VLI;BY>:*"94U.[ED@"0RR>65WA\#9M;@O`_Q"U?0I](TN^TW3]'T+4-6 MTZVTWPSGZC?SW-GK6GQSW:QW5O8I"]HB.'C4Q%&^J M;FUM[NWGM;FWAN+>YAD@G@FC5XIXI4:.2*5&!#HZ.R,I!!5F!X)KQ'7O"NB^ M`+"RU^SL[^^L;#5=/AF&H75YK$?A'2[R26TO=8\.VKK//82:>+B&4+:8B1(C M*\8%NDB=M#$1J)X?$>]S)*A3CI&+BFDXK;FDW'F:7,WK=M68>WJ0L:J%.68J M1@)@LQWN`P0$;B6X&Y@<@$FL3Q+X6\->,=%U#PQXPT+1_%/AO6K9[+5_#WB' M2K#6]#U:S9D=[34])U.WN[&^MG=$8P7,$D1902I(4CYE^&>NOH*]5O\`6KS5=*UN*ZF6[\*ZUI8<3!=3;$MA?VMDT9D>:)/)G?:3 M].>'?$VA>*K"'4]#U&WU&VE+#=$)$E@D4Y:*YMYTCN;.;:4?R+J*&4QLD@38 MZDX8BA4I2BG=VE"?M(W2A.$E4CKHU)2BG%IIJ\9+7035U:R=[73U35]=/2]O M/<^*/VROBMXS_8Z_9HFU?]F#]F/6?C+XN&HZ-\.OAO\`"7X6Z%9Z=X?\.:EX MI>YTS0O$.NZ1HMO&^G>!-&UB:R76HM(M(4GENH;:ZN]!L;V]\0:7_,%\;?AU M\1?@C\1?$OCG_@J=<_'CQQ^W!\:_AK!X_P#V%/CA^RMXG\0^)KCX3_$/X>V\ MFKZY\&?`GPT\,1Z99>'M2\&:YK^B7^MSC3_$/@WQ+H-]J-Q97\.J3:QXEUK^ MVR=%:-F$22OQMW``\E>=Q&1@`-U!)4#@XQ^+/_!1#]FK6?A5I'[37_!1WX6Q M>./BM^U/\/?@`?#_`.SWX8UZ,^/]!^`KM-/HWQ$\>_!;P(;&=8?&6J>#=:U+ M5KZQ:'4Y-0NM&N;>.2:V\07^GI]SP1Q%A\LQGU"O@J+J9I[2C7S*56=+&8RO M6K8*&7Y<\=4]I3RW`?68RGF-2%.3QN"G7P]>,TJ:7F8["J<+PNE2@_9TDN:A M"_Q5:E&Z52I%7=.SCRN*:M9M_6__``3:\<_M0?$/]CGX->+_`-L?PQ/X5^/F MK:/K!\5Z??Z/%X?U6[T^SU_5K'P?KFM:!;Q06VB:_KOA.#2]5UG3+>TLH;:[ MOI#]DLBXMS]YI\WS'J,KW]^Y`SUQ7\?'[$OQ;_:J\+?M3?LT0>$?VKOBO^U] MX(\<^)/%OBOXZ_&>_P#C)J'CW]E>3X`3?#@^*M:7XE^'_$6J7\W[+7[1/P=U MZ6UM=-\$^?HEKXST.XTB\MSYAMOA[X]^)[ZQJ5AKW@[P!#.[7WB73=+TNWMM1MO%-F) M+*[63SIM/AM]0\,ZGX@\_BCAC%87'YECZ/U6OE\?;9C7>`7L<'@8U\?*C3HN MGB)1J8>]52AE^'K>QQ%;#+VBP]-1<8ZX3&QJ4:<94ZD9*T/AYO:+3]Y3MI.F MM'.2T3LWW/N+Q%\/M-UK4&U9=1U73K^[LX])U$V7]GS6FK:6DCRI9ZII^HV- MY93QQ!I!%/'##R!9[9],N86@LA#;Q@+''(OV&N"!N(8_>'<#W'7\#U M_6N1\0>"]!UNYAU:XTJQDUO3H;@Z3J4L"/+9W,D+1Q3[&813&W=A+"LRLJ2K MN7:26KYC"XEKE=>"FE%:"*_;>KN+@6'G/&<2:= MXE\-ZPC*C+JL<,%K-I]E/;O.EU'"]J1'<;/?/"OQ<\*>(KG3-.MFUN$ZF)8M M'U+5-)FLM-UQ[3>LYL;H,\9E)AE8V\YBE4@Q^6'&RJQ&'49>VH_O(U/>GR*7 MLZ-TFX1;;T3326C:BI6LT!ZS12`@D@=L9X/?IST/X4M>UG5)4*,8;FVDAN;>4*Q,<]O+%/"^)(I$D56`!^"7[*?B# M]LNS\>?\%!/#7P6_9R_9E^)_P8UO_@I_\5=,\<>)?B1^T=XV\*?$2V\.^(X? M@CIOQ7.F?`:#]F77OA]XSBT;P1>:KJVEP:U^TEX0/B:]^T6=WIT+0P6.MX/_ M``5'\&:A\+/BE\"O^"A/_!/;2=+\1?MNZ!\)O'NA>(O#'PP\'>$?'J?M&?L% MGPM9ZYXYO_$.GMXJ\&6?B&R^#OB"W^&'Q"^"%_9^*K>?QCX[M?"OP(?$/Q'T?3_\`@IK_`,%+ MK+2_B!K_`(NLX=.\6:YXWT^V_:YCM/%>L>)]/M[>P\0ZGKT-_>ZU9P0VNI3W M,$2(OO7P<_84_9M^`?Q*^*7Q<^%N@_$S1/'?QD\.V?A#QU?ZQ^T9^T?XXT9_ M"VD7M]?>&_#WA#P=X\^+/B;P9\,]'\%G4]0L?`%A\-/#_A&V^'VAWEQX=\$Q MZ!H$K::0#\F/VS-)^!\'_!)?X!^.?V,K/P9\3/"GQ7_;/_X)Q_'+P?XK\2:J MGAB+X[?$SXH_M[_`'Q9K7Q`^,/C?0O!GB?5M/\7_`!+\8:O>S?%+Q6/`GB37 M]`O=0UF!/!]\^DP^&*^@_$>M?M7>)O\`@HG_`,$\)_VF/@'^S-\+K'2+#]K^ M3P9K7P5_:@^)'[0^NW6J7GP>T2WU6SU+3_'_`.QM^S-#X5L#IZQLNI:5KWB6 MXU"7-E-;3XHW?ANV_:ICT:X^(MKXRT[3_`!;;^-IK)_$L M'B:PLM>BU-=5M8+N/ZF^(_[!/[./Q9^+GP:^.GCB#XZ7WQ0_9^TJTT;X2>(- M%_:Z_:X\'6?A>T@3R-2FN/"W@SXX^'_"'B?5?&%B(](^)6N^+M!U[7/BIH,% MMX?^)&H^*M$M;?3X@#\"/VA-.NM#_P""?_[:+^`O#'A:Z\1P?\'!_@36O#>@ MZI?R>#?#>K^,K[_@I'^SC>0+KOB'1O#/BN_\/6NOZS=.GB#Q/8>$O$^JV<%_ M?ZHFA:]=`Z?>?3_@WQ3\4_#_`/P71^#>J_MA?!_X6?L[_$OX^?L4?&7X7_L] M1?LR?$C5/CYX(_:$3X;>)O`_Q*^*MO\`M"?%'Q;\(/V=O'5AK?PAT"#1I_@K MH-]\'+SPR+7Q7\2(X_'EGJ#Z=H_B7Z^/_!$G_@GF?#^K^$SX0_:;/A7Q!\46 M^..O>&3_`,%$_P#@HO\`\(_K?QJ?Q7:>/'^,&KZ-_P`-6_V=J7Q1?QS86'C- MOB!>VTWBQO%=E:>(CJYUBVAO$]W\(_\`!-S]DWP7KGB[QAIVA?&K6_B-XS^' M^K?"R\^,/Q"_:Z_:\^*OQT\-?#_7IK6YUKPQ\,/CK\3OCIXO^,'P;L=4N[&Q MO+Z3X2>-O!-W<7ME97LERUU:6\T8!\2_\$\?`/@O2?\`@C?X$\3:5X9TC3=; MTO\`9(^/_@?2[VQM([4:5X17Q3\4=5/A[2[6`)9Z;IDNH6]K^2.X24VL]J[6C0"\O1<]A\/_P#@FI^R M/\+/V6_$/[%WP^\._&?PM^S9XE06MU\/=._:X_:[-WH^BNULUYX1\$^/;GXZ M3_$GX=^`M7%M)%XA^'W@'QAX:\$>)+?4_$%MK_A_4K?Q-XABU/Z(_9X_9[^% MG[*_P?\`!7P%^">F>*-"^%?PYTJ#P_X&\.>*_B7\3OBQ>>&/#EE&D&D^&-*\ M4_%SQAXY\7P>%_#]C%!I/A?PU_;[:%X6T.TLM"\.Z?I>CV5I8P@'\Z?[1GP] M_:0^#?@VX_9A\1_"+7O$GQO^/7_!9CX9_'_]E3]K/1/B'\*+H>*=#\5_M>:/ M\?O$4!\-77Q!MOC]I7BSX!_LE^%?'_PQ\(OV>?C+%\0OAAX+\)3> M.O'_`(0T+PUXTO\`1?$>A#1OZ"_`7[*/P)^'/Q:\8_'C0O"6KZQ\9?&\_BC^ MT/B5\1_B'\2OC!XN\/:)XRUBPU_Q'X#^&>K_`!9\8>-;CX._"C4-8TG2+]/@ M_P#"9O!7PLL)M'T<:;X/LX])T]+:_P#"_P#9D^"WP?\`&WC;XE^#?"^JW'Q* M^(CW$?BSXC^//'GQ#^+7Q!O=(GUB[UZ+PAI_C;XK>*_&GB?P]\/-+U6\FN/# M_P`-O#FJZ3X`\-(EK:>'O#>F6=C96]N`2_&NU^&'A[1]8^(WC;P-:>/]?;P9 MKWPQ\/>%IK2VUO6/&]MXX,1O/A3X4T369SHIO/B9?Z?I>F:W&\5E9:I9:;I] MQXPU!/#?AO[5I?G_`.P=^SOJ?[)W['O[/G[.VM7]C?ZO\*_AYIN@:H-(FO;C MP_I.H3W%WJ]WX8\*RZB\FH-X-\(3ZD_A;P:M\YNX_"^CZ1'<8F1P,OXB?L'? M`7XI2>%;CQ9K_P"U/%?>"M8^(&N^&M5\'?MY?MT?#;6M/OOB=K$FM^+(I-;^ M''[1GA35]1TKSY&TWPOH.IWM[H7@#PN(_!G@'3O#/A&*+0T^@_A/\*?!WP5\ M#Z7\/?`H\5/H&E3ZG=K?>._B'\0OBWXVU6_UC4;G5=1U/Q5\3/BQXI\;?$CQ MGJMQ=WMZC#916>F0746F:?86EL`>CT444`%%%%`!1110`4444 M`%%%%`!3717`##(!!P0",CU!!!_*G44`>*?$WP;?ZILNM+TU=5#)Y;L(6C=@ZZ7PP\)7WAO2DU3Q M!,Q\6:IIVEVWB-WN#+;EM$ANH+&4YROVO[%.L=Y=!PD_D1'8HC`KUFN!^(GA M34?&>B+H=EKDNB6UU<1)JS001RRWNEF2,W5FDK$-%YB*04_U-SGR;D&!F%=" MQ$YTH8:^+H][^'K/59B?LFESWB1-$DERJN%NFE2W68QQ`N)!(/5XC'UU'E^V?#+Q-X,71M-\ M):)XH@UN[T;3E4LZ7%O-=P1RLDEU;)=)$+FV69RB26P:,1^7C*88Z8K"TH4J M7LI)WL$?PYI/B7QE8VMIKVGVVGZ ME;@ZC#YMS:ZEI=U@6)_MVDS(AB7!+9#YD4';@AAC:^ MX$_*4.WACET8"OSX_;6_9,U/QU\,?C3\1OV5?#'PV^'/[=&O>`)=`^&_[0:^ M&/#FE_$33F>\T]=3T6U^(IT>YUK1I-9\.0:GH-AJY>>329KVVN_FCMB@^HX< MXAH4:,/?A!9>+M'OO&_@:^U;1K'4[VQUSPM%>R^(=*BL) M[Q8&EU.PM_D\MV8"0$>[*['&0.6*\9/?`/.,9'/<#GD@9/\`&=H'P/\`VI/' M'[3W@31M#TWXF^"_%'[/_C'X>^-OV@/VUOVK-#\!P_M1^"_%7AWP-J>K>-OV M'+M=-U75CH/E6T/]#/[)7_ M``4Y_9G_`&PM6\+Z'\/H_B5X/UGX@^'O$7C/X3VGQ4\$7'A1/B_X(\'Z]>^& M_$WBSX<:M;ZGK.B^(++0=8L;VRUC2'U&U\5Z0D7VK5]!M+7S'7GSWA2MEU.G MB\!B)YCA:6&A7S"5"ES4\OG656I15>492:HXBA2JXC#*HJ=6.&INI4A&$5*4 MX/'1J-X>HO95+\M+VCM*JXV4E&]HRE&6D_9WAO9OI]Y>+_"]EXL\/ZCX?O'E MABU&W\M;F+:);>6*5+BWD7Y"7"3QHY1@R.%VN#D5YEX=^$US!K^G^(O%&I6= MYJ&FWIFMH_#\,^D:3>30V+6EMJFIZ5/+-;G6Q%(UO<7FGK:_:H4C2Y24+Q[L M'4C(S^1'8GOCT(^M1W,)N+>>`22PF:*2+SH)#%/%YBE/-AD',=\;_`,+@ M&OEJ=:=.#A3J-0DW)QBTTW+1OKOR_>NZ/4V=GO\`U_F2@8[D],`XXQ]`/US2 MUR&FP:?X"\,11:MK=Q+I^D6Q-SK6N7?F2E?,8F2YN'(4#+JJ*!G.1CI746]U M;W<,-Q;2I/;W$:RP31'?%+$P#+(CKE2K`@@Y&?2H2ML!/1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M(5#8SGBEHH`\S^)7@E_&'AK5-+TQ[2TO[R;39IGFC=(=2CTRX6Y.G:C);>7/ M);W,+20J2[)&TF75T#(?$KJQ/@#7]#\0ZI#<6'V.;5U\,_#O3K^WUN[N]6U1 M+6WGCTF]CB^TVGA_>PEN+6[C/V:7RO(498#ZYK&U'1++4+B&_:"W75K.TO+; M3=4:!);O3OMR*LSVSD!T+>7&3M<9V\;3DGIH8ZK2<#[2_L9/^$?LX M4PELP#+/)J$B3Q?:T08#IOVDL=OL;!6)RQQP,#'\)R.0N[(8G@-QSQUKXHNO M`&KZ)875AJTEMXLV&L7=JBVEQ MILD<]G+&0XE$P);W[1_BII&H:K:Z:;.6/2M2OCI?AWQ1!>6%]H>O7HB\\V\4 MMI'BWSX:7M5SS@UR\J2IJ.UFT[INT=6DN: M3VN:K5?U;_@VW/GK]NO]D>;]K7X5>%]!\-^,H_A]\4?A3\6_`GQW^#WC"_T: M+Q%X$]4M-2O]%US3H[RVO197C7&G7$=Y&// M_GQ\<:-^TY_P3U^('AWPCX5^"/P(_:&_;R^+'CC]IO\`:8^!=A\./"WB[3O@ M]^S+\*-7\/Z4OQRT+X5Z1KGB'POXM^(FN>/;V&ZUFS^%=MJ-K8Z7JEUK;CC&.,]?_K5\K_M/?L;?`S]KG3?"UO\`&#P[J.[ET^^@5 M%O+&XV)CU^'^)5ED?[,S.G#&Y%46(E4PKI7J>WJQ5HRKTYT<3/"3JQI5,1A% MB:<*WL_9J4:57%4,3R5\)"I/VU)JCB%'EC5Y>=)6M\%TKNV_1Z]#X[_X)9_\ M%`?%O[;&F?'+PE\0+/P/J7C7]G_6_AWI^J?$GX6V7B?1OA_X^TWXF>%+OQ7I M$>'_B5X&UF>[G\.:_$ENMQ^]>W@_6Q3E0>N?\:^)9 M]1_8_P#^"=/@'3I?$_B3P1\&-`^)?Q!T;2-0\8>*[^3_`(2'XI_%76=,ATX> M(_'/BFZ6ZUKQCXVUC3M$2\\3^-O$MU/<"WLKS7?$NL6UE;WVI1_;,9!12""# MGD9]3GK@\'(Y`^E>1FWU*KF%?&Y7@<1@%&&(G3G-N$N: MO.I.4*$ZE.CSJDY+EBC6A&<*<85IPG523DXM72]%LF]=W?YE>^L+/4K::SU" MV@O+2XC:*>UN8DFMYD;^&2*161P",C(X/(YKG/$&MCPO::?):Z%JNK12WUCI MD=MH=FDYLHKN58DN)XHR@BL8AA2T4OK^A_PHWKZ_H?\`"H:*`)MZ^OZ'_"D:5%&6;`SCH3S^`J*O MG?\`:;_:H^"/['GPB\2?'/\`:#\;:?X!^'?A>.`W5_*&RT+PS MXWC1)+=21QVT%Q+#=*C6Q%2G0PU*I7Q%:<*5"A M1IRJU:U6I)1ITZ=.'O3G.348PCK*326I,ZE.E"52K.-.E3BYU)SDHQA"*O*4 MI/2,8I-MO1+5GT0;J!3@R8.<8VOU*[O[OIS^G6G^='Q\W7&.&[].U?QW?&W_ M`(.U/A?%?7&C?LQ?LD?$/X@W=U'_#UOJ]N7ET>YNHXYI(/ MT&GX3>(56-%K(%"5://"EBLRRK`5IQ?*TXX?%8Z%96O9W@W>S:BFCY>?&O#4 M%4G_`&C*I3IRY9RI8/&U81DM))5J5"K"IK>W*E:VM^G]SZ7$,A*H^2"01M<< MJ<'JH'!IWFQEMN[YO3#?WE7KC'5U'X^@./X1OV;?^"^?[6'[8OQ6LOAY\1?V MT_@'_P`$]KKQ1K\&D>#-1A_8_E^*_@B[-]-#;:=8Z[\1/&_QHNAX>U*>9Q;2 MWNMZ%IGAB/:FH7&J6-K)<6EA_0O!\*_^"S?PFGLO&7AS]L3]F7]L_1[7R;[6 M/A5\4/V>;?\`9TU/Q)I-N6FGT[P1\4OA7XH\566A:_JD31Q:3J'BCPIJ_AR. M5X)+O;:,]P_GYYP/F7#E2EA9I5)U%!JC2S!Y5'*JE5 MN7LW*GCI4(U&KUG%5=XJ*>E MG*A&5W[T(V=OVDWKDC/(.#P>N`?3T(I/,3.,\_0_7TKX<^)/[=GPQ^#O[$%S M^W5\0/"GQ`M?ASHGPZ\)^/\`Q'X*T/3=#U+XCZ(OB34]!T&Z\-OIE_K6@Z'< M:WX:U[7DTS7$_MZVM4-AJ$MA-=A(89_QN@_X.MO^"<=UO MK^A_PJC:7"7=K;74898[FWAN$5P%<)-&LBAP"0&"L`P!(!R`3UJQ7@M--J2: M:;33W36C3\T]&>JFFDTTTTFFM4T]4T^Q-O7UZ^Q_PHWKSSTQG@]S@=NYJ'L3 MZ#/\O\:^*_V[OVZOA'_P3U^!*?MQT^==/\`$'B3PKIYL8O[-N/M8_*MY]YVZ8;#8O'8O#8#`X>IB ML9C:WL,+1HP-DUO'K>^5?$4L-3JUJ\XTZ-"DZU6I)VC" MFFDY2=G:*W;ULM?7[*OBS\0/!WPV\-WNO?#_`.&EIH-IKWC?Q#IWAG1YM9N]-^,>K7MKIZ:C MJ=N;J>VTZ]F2!9I([>4IL/\`1@N=JY&#M&1G.#CD9[X]>]>EF^09YP_4H4<\ MRK&976Q-.5:A3Q=-4Y5:4)UDU:YS8#,\#FD)U0=Y-O7U_0_X4;U]?T/\` MA4-%`$V]?7]#_A1O7U_0_P"%0T4`3;U]?T/^%*&!Z'^=04].I^G]10!+1110 M`4444`%%%%*RO>RO:U^MNU^P'*^+O">F>,=$FT/5OM(MYIX)XYK60KUGB=DE0F*9$?9.CP.`4D&T\?/NL^&)]`\86.M^(!9ZEK^IZO+I?P]%GID. ME:(FIVMA)=Z;J_BQ+.WLUDU&>\::TW1L2MNH;=)`$A@^K*P]>\.Z5XEL7TW6 M[2*_LG9)/)E#J5EC;='-%-#)%<6T\3?-%<6LT%Q&P!67&5.V%Q-;#VIN[IOF MYFVFUS)*5FGSKFLN:S7,HI/H!X_\+_'WB;7[Q+/6U6_B?3]5>[OX=+&G?V+X M@T/4%L]4\/7PCN)X9&\J>SO-/G`A>XMGFD;>OEL/>?,C/&]>>!\PYR2!CGG) M!`QU[5\F?$'P9'X=O;/2;.?4?#_@>YTV]U.6ZM8=:U33KGQD+G]VGBE;.:XU M:>TOM-%O9)*TI%L\9:*2)I"!ZS\)[/7;+2K^/5K5].TZ35W?PUIRV-Q>>==V,=XS7%M;2B!R"-J[XFG1G!XFCR13:C.DDH).Z2: M3<;MZNT(R24>:33:N/\`R_(Z/QU\,_AY\3-/T[2?B+X%\)>/-+TC7-+\3:5I MWC#P]I7B6QTSQ'H5REYHNOZ?:ZQ:WD%EK6D7:+-B2?#O MBK\?_&?PS^.O[/GP>T'X`_%3XB>&/C/?^,;'Q%\5_"=KHTW@7X0Q^%]$BU6S M?QE-*C)6DJG)4<5:%24 M$JMXMDQA!2YE"*D]')))M=FTKV'JX&YF?C.`&`7:06!4`@-G"Y^8G(&5.WFI M%8M@@<'OG^7K7R?:^%_VM$_:LU3Q3=_%#X4W/[(<_P`-K>RTSX71>`M5M_BS M;_$Z&[D2;5I/&ZZFUA-H3V^\O#/#.LL$ZV,6D6%S;'6[GW'QC\0]"\$06BW\ MC76J:A/!;:9HUNZ?;;UIKB*#SEW%O*ME\PLUQ*%1F7R@3*RJ_X^_\`!1__`(*G:;^R M?JOAG]FW]G;P;:_M(?M]?&&>STSX-_L^Z2T]Y8V,U]J"P)XH^*U_I=Y!+X6\ M,V=A'=ZFMI<7FFZAJ=G:7>I-=:+XG7Q-1M0HX>E!.I5JSDH0A%N36E^/'8O#X&A*OBZBIT4U%-W_>5)22I MTH26'G>'_`(>7%EI= MU^S5^S8+KR[G3=&^%'@":Q.GW?B70+7[.ESXWOX\-J'GZE;PW6L6D7BW4?QC M_P"#E[_@E]\=?&WQ"M?V]_@M9^+?BEX/M?!FE^%OC1X#M[K5/%FO?#U-!N4L M-$\7>`_!L5E?O-X+U"P=CXUL]$MC+HVKV9\1_8;S3]8U672_U;PXJ<+9=Q5E MV!AFU&688BEBJ-7B.="B\'AL3:,883A^&+IRC#$SJ^Y+.<;&48P:>"PG/:=3 MX_BB6:8C),16G@9/#\U)QRV$I^TJQB^:<\=4H2=7V#@HN&$PS;J7E'$2Y7)+ M\Z?^"57PB\!?MU_M":E^S1^RETI M=9\(>#=1T'3_`(A7?_")^&/A+I5__P`)8-3U/2?A!X6\/V]CIFF76F>(KOX@ M6*O"&KZO=/+* ML.L+X-T_P3XATNVU&_G:2]O[:[UR\A>5[I--U*YQ&W\1'@GQKXV^&7BG3_&G MPZ\7^*OA]XST*Y:32/%'@KQ%K'A?Q%I$\,\S&33]6T6ZL;_3I27:*?[+<1M- M;*EE=M);JUN/VU^"'_!Q]_P5.^#.G:9HFH_%3P)\;]'TR**""W^-_P`/M)UG M4Y+:`#$=[XK\'W/@3Q?JTKX'FWNL>)+R_P`X<7>17[=Q7PIXA4,QI9IP-Q+0 MP^"5##RGEV85Y3Q.*Q5-J56O+'XC#8Z681Q"E*--8G&4_J\$J=.E2@XH_.\G MSOANKAI9?GV6UZF*:E#VV'IQC2H7T@H86&)H*CR6W4)SJOWJGPZ_D!XF^`?Q MJ\*>)?$'A+6?A?\`$*35/#6N:GXB^*+#Q+^S)XV7X8 M^%==\7:=K.F:QK?PWU#2+?Q%X+M;W^V=/M3=2>#O/U/P=:O9B\MH]"TC1HY9 MGOH)L_GM^R)_P=B^"O$.MP^%?VU/@#+\-[.Y9!!\4?@A&?%WA>\2^TK5;"Y,G*RK!;R07-O,LT%[I]Y!;ZCI] MVD]IJ%G:7,3PK^8>+O%?%&-R[#Y-Q9P52R:I/%4L1EV<0Q2Q<*M>G"K/$JC4 MHX=T8*K1;YZ7MJ;AS13CSE0E"%2? M/355)\_/2DXKF4IM\KBY-79^5'_!;3P?I7@3_@BY^UKX/TA#_9WAWX5^`M,A MDDC@6:[DM?BC\/1<:A=K"B0B\OKKSKZ[>!%62]N9Y@N9&:O\O[3\1ZEIY&%1 M-4TU2%(&U#=*P!5>0FX;NFWO\`Y1%?MK_]B#X1_P#5L?#^ MO\LV*5X+B.>/;YEO.D\1>..11)$\4J;ED5ED0O&A:*0-%(JE'1D9U;[?P$A* MOP7G=&*4IU>(,932F[1D='Z?+^)W_(_P`IUY8PP6%D M[:62S#$2DTN_)"5]K[7U/]>_XZ_MP_LC_LCZ-X9'[2G[07PR^#M]K.B07NC: M)XM\200>)]8L+:'R9]2TOPI9"\\2:AI\*/'GB"ZCL?#O@V;7KOPMXH\17\W,&GZ! MH?C"S\/ZEKE_<`$066EV]U=3L"L,+L"!_!?H_P#P1_\`^"O'_!130]2_;5\1 M>#AXLO\`XLK=^+M&NOBM\5-(\*^+_%^D7@-WHTGA?P[K-ZT>B^$#!,D'@W3M M6B\/V5GICA-%L;:RN6N;S\5O&_@SQE\,?&?B3P#X\T+6/"/CKP/XCU/0/$_A MW6H#8ZSX>\2Z#>W&FW]C>P)<3K'C MF&%PW&OUWB#`\WUZCE\*%3`82O.2P1'W\/MJ^B_VJFG>&I(_$OC#P/I/VC5S=2RP.^N+=!K`&VL[@@A?) M_P#@WS_:^\7?MA?\$[?`VJ?$;4+O6_B'\$/%&K_`'Q3XCU"Y>[U'Q3#X,T;P M_K7A/Q!J-S*\MQ/JESX+\4>';+6+JZFENK[6-.U#4965KL1IX3_P=(JJ_P#! M+NZPJ_O?VA/@Z&RJMC8?$[+@L">JX()(*LZD8=L_DF09/F&7>(>`R!8MX#,< M#Q+A\MCC\/"GB'1KT\0J<<31I8F+I334X3A&I&TKI5%&S2^YQN8X3%\+XS,W MAWB,+B,KK8AX:H^1U:%?&FCZ]I7A/3OL M'[0^KWRW>OWFGQ:1#+::-JMU%)>KY=G(7,G^0?_P`$^2!^WS^Q#\D1/_#6O[.B@^5&,*_QA\&1L-H4*Y5!C93T(#9XX++D@#&T`=AMXS],?:^-^79GEV:9##-.(,;G]:IE M>)>'KXW!X#"5,'3>,C'V"C@8QIU%*=ZCE+FM\-[62\/P_P`9A<9@,?\`4,NH M972I8RC&6'I5:U=5&X)RDY5FU&_11?KW7QUXL_X*(?L&^`_%'B#P5XW_`&S? MV7_"/C#PIJU[H/B;POXD^.OPVT77_#^MZ9"Y MM+JWCFAD1HY$!!%>K^'?VGOV=/&'PHU7X[>%/CK\(_$OP6T&'6I]<^+.B?$# MPKJ?PYT>'P[/):Z]+J?C*RU.7P]9)I%S!-;7YN;^/[+<1202[959*_RO_P#@ MJJH'_!2O]O#`!+?M6_&\DLB2&OB%\2/!O@'7O&/BCPM\(OAOIFK:F=<\5^.?$$FJZOXW\;Q65PT M)@TQ+VQTG3=9UP6OA?PM8`W45Q:W>J7EXWT"\",#/)LHS2GQ,J-+%PPN*S9X MS#TJ5#!8.O@OK%5TJEN>O657DI4_:>SC[SFY\L.67CKQ)Q$,;C,'/*E6JTZV M*I8.&'G5G.K.A*2IJM!Z1C+E7,J+E)IV2YV?Z@GP2_X*/?L+_M(_$1/A-\!O MVH_A'\5_B-+I>I:Y;>$_!GB1-5U.\T?1@K:KJ5B8H1:W]C8*Z&ZN;2XFBC#I ME\NH/VMO5EW][X/\`$VM3 M6=UJ31%88]1336GN$F)5I`LC_?'_``<1_P#!8KQ[^R)I/"GQO\ M;>&#XG^+7Q$L;6&75_AU\/M=AN;#P_HGA"\FFE@TSQIXP:*_U*;6#:27OA?P M[;:?=:68=7U^QU/1?S_-?#^%;C7`\)\(9G#.H8O+\)BI9C5E0E0P\G[=XN56 M>%]HE0HJG#XHN<'.,%S2DK_3Y?Q-.'#]?.%I1KE[)6Q M"C*7Q+WHNUE-N]M/WV_:"_X*"_L4?LJZG'H7[0G[37PA^%WB.>!;J+PEKWBN MSG\:/:D1D72>#=+_`+1\5-;$31,)QI'E%)$?>492?%?AU_P6+_X)B?%7Q%9> M%?!G[:?P4GU[4[C[)IUAXAUS4/`YOKIW6..VM+CQQIOARTN)Y7=5ACBG9Y21 MY0?G'^=U_P`$Z/\`@FE^T7_P56^,WBG2/"&NMHGAOP\UCK?QD^/'Q`NM4\56 M^AOK4M\-/@E2[U`>(/&_CGQ#/87,EEIDNM6TLEI9:AJFNZY86*P/LZ)H'C36K#PIJG@CQ;X'U+7KL:;I.I M:MX1?7/&FFZAX,O-3DM]*;6;;Q(CVFI:EIEOJ&EP03_;X?O9>$_`67YMAN%L MUXXQ5#B?&1P\:="GAZ#PE.OB:4:E.$I2I34(57S>RA5KTJ_+*$7!3?++YN/& M/$N+PO\`:V$R&E/**4I2J25=NO.E"S6C9UR:NIU/T_J*_P`\7_@W MM_X*X?%+X%_M"_#O]C'XR>*M7\9_L]_'#Q-9>#_`%SXEUR^O[GX-_$;6E>W\ M*6WAF[U";G*G.?W/#^>8;/\`+X8W#KV<[N-?#R^/#S3TB^\9 M*TH25TXOILK%%%%?(GMA1110`4444`%%%%`"%5)R5!/J0">.1U]^:Y/Q!J/B M&QO=#AT70HM8M;O58H-:N9+^"R;1M->/Y[^*.8J;LQ.%)AB)E;)P`N67K::0 M.3TSRV`#NXQ@C!)XXP.:%934W%2LFN63?*[[-J+BVT]5KH^X#8R=H+'YB`6! M.=O7W./KDYQU-2$`C!`(]#R*Y&ZTC7Y_%6FZQ;^(&@T&TTN\M+SP[]DC9;V] MF>-H+Q;UEWH(U0JR%&[;-GS9Z*.\ADG>V2:%IX`AGMTD22:)91F%Y$#B2%'` M;8TL8\X#*8P10!:\M.?D3G&?E'.`0,\Q->:O\`"OPG<:WJNNZC93:O M>ZL\#%]3NI[L:6D#)*L6C2-,LVG@7$<':8;X_9?T"3]K?\`:ADU#XC_ M`/!0;]H2PNO&'QC^(?C>\37O$WP]C\80VEU<_#;1K^$/IL&J6D$5M:^-]=T] M6&JZE;MHFCW$?A#2=+LY/YV_^"Q_Q"3P'_P<)_L\^-/VC/MD7P#^&GBS]D/Q M#X?GU^&\N?#-K\+=)U[P[XC\;ZK961N?L4]KH_C!O&=SXG2WAEEDCL+A]3BF MMETV.U_O/\(^,/"'COP]I7BOP1XE\.^+?#.M6D-]I&O^%M9TS7=#U*TN(DEB MN;#5-'NKS3KV!XF1HYK:XFB*,"CE6!/ZEGV#J\,<#\-X3`+G_P!$?:8S#QDHXFK*#J+DBH/X[+J]+-^(//ACXLM?VB;;Q3\//&GBCP+XEBMOA':W M-G'K_@WQ!J/AS6UMIG\86TKP0ZMI=U'"\L=I.VQ&>")MR#]Z]>\4^&?#:0MX MA\2:'X?6[8Q6TFLZIINFK/)AOW=LVH75L)YN"?*B$K''"'[_`%[]G/\`:-\37/C>_P#%&F:=--I_PS^*6OM'<>,/ M"GBFXMU>VTFV\6Z[]M\8>&=1NECM]6GU?5M*M[J&;0Q;7F/A;P_PQQ'GM;)N M)*F(P[Q6&YLHG1K+#PEBZ5IU*$O=M.5:BW*DHVLX*,4VU9\79CG.4Y?3QF40 MIU%2KMXQSCS)49M6E>TFG%J\IZ6CTT1_19\$_`7_``1#_P""YU[\9?&7@[]F M&VO?'/@'5?#LOQ"\5WGA?4O@-\1M1O/&EIK4VCZW-J7PO\8:??\`BI)KC0=2 M6?4/$?VNW-U;O#(EQ(DLT7SE^TS_`,&G?[-'BS39]3_95^.'Q%^#'BI//N8= M$^)*V_Q6\`W3*0T=I$]M:^'O&FB`9,0U&?5_%30H^387#E$?^.[]B']O/]HW M_@GU\7&^+?[.?BZTT75-4T^'1/&/A77=(/B+P7X]\.P737<>B>*M`\^Q:YCA MNV9].U/3=4TOQ#HDDUZ^DZE:QZA?QW'[A^)_^#L+]O+7O#%[I6C?!+]F/PEK MMW875L/%]CH'Q'UN?2IY8FA&IZ7X>UCXAW&EM>P22"2VM-9DU:RPI%SI^I1; M[=OUS'\!^)O#>>P7`>>XI<.U94OJF$S+-J5\#RQA2Q-/$X7'1J*I&552J4_J MRG*=-:14U%2^(PO$?"V;8"7^L.6P69J,W5J8;!\LZST:E2K4&I)QTC+GU=TM M=3^?']J+]FSXH_L=?'WXB_LX?&?2[+2/B'\,= M+XO%/[7'[/5Y?W5WX!M?#7@;XOZ%I!9FL/#_`(G_`+7N_"?B:YTV"5W>V/B3 M2Y?#$5['&YCED\,6,DB^?).&UAB6*);.VM;.RM+>UTW1]&LK>RT_1M,M++2=-M M;.RL[>&/^\K_`(-A/^"?WQ/_`&9_@G\6?VF/C5X:N?"'BC]I8>!K7X=>&-8B MDM/$ND_"GPI'KE]'K6NV,L-M=:)/XWU[7C>6^DWL4=^VA>'/#VL7%O9C6!:I M]1XLXFG@_#3$X7/:^'J9QC%E>&A[!.%*OG.'K8*OC:V%IRM*E1_=8B:M!2G2 M]R5E-V\3@N$JW%\:V5X:=/`PJXN;J2YDX8&>'Q%*A1Q$?MU82E1BW-N2FD_B M1^D?_!>L?\:B/VUCG.?`/A$?^97\`'/Z5_EGV\,=U>6EI-DPW5_;VMRFT?O+ M:ZDCAFB#Y!43)N60@9V`QC(E8I_J7_\`!>LJ/^"1/[:J!@0/`/A'D M_MS'WDMDUD>7V>VC4I.U^K^1W^)[7^L.5Q3T>"PL9>499C7BVMK>Y4EKT>O0 M_P!H+PWIECI?ACP[I&G0)9Z;I>AZ)8V-G"-L-K:6%E:Q6EK`I)*P0PP10HI) M81J`2W?_`"T/^"Y%K#9_\%9/VVH8(HXE?XFZ'=.L2[5:XO?AMX'O+N8@\E[B MZGFN)"?^6DK`9`!/^I]I1']DZ9R/^0?8?I:1Y_+O7^67_P`%TOF_X*T_ML%? MF!^(WAG!'(/_`!:SP#W%?!^`%Y\99_"6J>28JHTEO-9O@E=]6[-K6[MU/I?$ MN$?[!RY7T_M&A!*ZMRRPM6#MVM&G';32[N?U5_\`!I,/^,#OCYZ_\-<>(_R_ MX4Y\'A_45[5_P=)?\HNYO^SA?A!_+Q57BG_!I,RC]@[X^`LH)_:V\2$9(&1_ MPIWX-\CU'(YZU_\'21!_P""7VPVOYW9V8=N7ANF]_P#5^I?R=MO(_@^_X)]?\G\_L0_] MG;?LY?\`JY/!-?Z^*?=/^XO_`*!7^0=_P3Z!'[?7[$.1C_C+7]G,\^B_&/P2 MS'Z``DGL`2>*_P!?%2`IR+/%[(7UB^\+>!-.\/#POX;29AMATC2M0UO7]6 M@@B$?F7VN7TUU]HD6"1/XW/^"JP/_#RO]N_@_P#)UOQN/X?\)WK'/TX-?V[_ M`/!K3Q_P3"E!X(_:,^+^1W&;;P81D=1D,O:-*4>JDNC6SU6 MI_1R4R`O;Z^^>1CG\Q7^61_P7CU/Q3J7_!6;]L@>+'N#=V/C7PAIVDI,<"/P MM9_"KP'%X42-/+CV0G0C9R0L-YEWR.SG"O)_J=5_$M_P<]_\$SO&6L>+=,_X M*'?!W0-9\4Z?>:)H7@7]HGP]H6E?;[WPZGA>T6R\'_%F5+1#>3Z&VBQ/X3\: M7\L;6N@VNA^%+[_1;/4-1U&P_)?!'/,!D?&$J>-G"@\URS$99A,0U!*GB:E6 MA5ITY-J/[NK[)QDN9)RY8V?,K?;>(>7XG&9#*IA85*SPF(AB:M)3F^:FH2IS ME;W[\L9.6D7JD_LJWX;_`/!.#7/^"QFC_#?X@C_@FA:?&:7X;W'CZ`_$F?X4 M>%OA[KMA_P`+!@\/:.RQ:Y<^*=&U#5(=7C\+/X/=,;0_%WA#6?`7PHBTW7-+FGMY3: M74]AX&)6UK15FM])\7^%/%":?X@'A_Q%;6$\FGW]I= M:1J6G:SHT]I_:D-M+IVDZPOZK_MO_P#!TW\5_C=\*;WX;?LE?!_7_P!FKQ'K MS64>L_&+4O'>G^*O&ND6MI.MU?Z/X&TG3/#%IING7&I+`MA=^+;R_GO+'3Y; MW^S=%AU":UN[?]QS]<80XJ<-,_X)`?\%8?#]_IWB/0_V)OCYI^MZ'?66MZ1?)H> MEQSV.L:791O+P2ZD$_ZJOA&YU*[\-Z)?^"AG[ M5_@O2[C]KO\`:'O/V5>'ZN/RW#XJJED3Q,^J)=1\%:-K0\9^$M/T>VU'2?$<08S:5$YCCBT2^N"%CGB`D>6W"YEB92K*`IK MZ),,48<)%'B7?Y@VQJ9"4P01LQ(TAPK&3)(/)(`%?.5SI7C+4M1DUV"33_A; MX2\/:O''5*%%0A-0FY7;J3Y7&:2BYRJ)WY8I.*O9QY8IL/I:BBBO/`\'^-W[-'P'_ M`&DO"Y\&?'WX/?#KXP>&C]I\C3/'_A71_$:Z7)=Q>3+>Z'<:A:S76A:IY9*_ MVIHD^GZDK%98KR-T!/Q1X'_X(K?\$QOAUK3:[X0_9*\&:+>O1Y#X#^`WP;^%B@?##X4_#7X?$[QII)@,;0GP[J?B]]2M?"CQ/& MLAF\+6&C7-RZHUY-/(OF5^GL<)0'Y>2^M]7?R_P",'P<^&OQ]^&WBKX0?&+P9H_Q! M^&OC:TM;#Q5X.UY))=(UNTLM2LM7M(;R.":"4K;ZGIUC>Q;)4*SVT3$D`J?S M]A_X(F_\$KX;C[1'^Q!\%(9!)%(K+IVLR;)(79XI%$NL.@DC=A(C>7E)$4@D M8*_JE16F#SK._9,^%7C_P")'C:_@U+Q3XP\06&HSZOKM[;6-GI5O=7TD&IV\)ECTW3[ M*V41PQ(J6Z`+D$G]#Z*PP689CEE25;+LPQV`KSA*G.O@L56PM:=.4E.4)U:$ MZ2L_=G%JR6BM9I:7/ MG3]G/]E#]GS]DGPEK/@7]G#X4>%OA#X0U_Q!/XKU?P_X2BN;>PO_`!+VD^TV27,ZPL92/W\A89";?>:*3Q MV/>,_M%YACGF/M(5OK\L56EC%7IRYE66)E-UE5;^*:G>VUG9E?5L/[%X?V%+ MZNZ7L?8>SC['V:^S[-)1MY-6WTOJ?F?X0_X(]_\`!-3X?>+O"WCWP/\`L;_" M#PSXQ\#^)=%\7>$_$&F:?JD5_HWB+P[?0ZIHNK6C/JTL:W6GZC;07,#O$ZJR M$%&#&OTD,+[-FT$%-I^X,-C&0,$#D`@8*@]L#BY158[,/Q>(QZTE>]UM8_-SQ[_`,$B?^";OQ4\;^+OB7\1OV/?A%XL\>>//$.K M>+/%_B;5=.U.34->\1Z[>S:AJVJWC1:M%$;F]O)Y)IC'%$K,V=HZ#ZJ^`'[- M7P0_99\"K\,/V>_ACX8^$_P]&N:IXE/A3PI;RV^F?V]K"6\6I:H%N)YY%N;Z M.TMOM(WM&6A3RPN&+>\T5M7SG.,7A:>"Q>;9GB\'2:=/"XG'8JMAZ;@N6FX4 M)U72C[.%J=.T%RP2BM$*E@L'0JSK4,)AJ%6I?GJ4:-.G.7,[R3G&*DU)MMW; MNVR'8WI^H_QJ&XM%FC,0`VN"KE@K$HRE&&&&#N1F7!RO)W*RY1KE%>;_`,#\ M&FMK/=)G0TGKULU?RE:ZMLT[*]TS\J?VD?\`@BG_`,$U/VJM:N/%7Q4_9>\' MV7C*[EEN+WQA\,;[6_A'K^HW-Q(LMQ_\`!N1_P2<^'WB6Q\3)^SMJGC6YTZ3S[33OB1\5?B;XQ\/&X1XY M(#?^'+KQ3:Z'K-HC)B33=:T[4;*X4XFB;`K]TZ*^CH<8<68;#+!X?B?B"CA5 M'D5"GF^/A2C32Y53C"-=1C3C&T8Q25DDNAY=3(\FJ5?;3RO`2J\SFYO"4'*4 MWJYR;@[R;U;ZO5[N_`^!OAQX,^&?A[2_"/P\\'^%O`7A+1E:+2_"W@O0-*\+ M^'-.@8[C'8:)HL%EIEH&?YI/*M%WX!.9MTQ[I5(/([>WM4E%?.RR6'G3Z=<+/$@DV2:=J M=IJ<68RR[@TEFB."PRK'.:ZNBG&4H2A.+:E"49Q:Z2BU)/SU6ST8!1112`__ !V3\_ ` end
-----END PRIVACY-ENHANCED MESSAGE-----